between	O
PC4	B-protein
and	O
NF-Y	B-protein
was	O
mapped	O
to	O
the	O
C-terminal	B-protein
region	I-protein
of	O
PC4	B-protein
,	O
and	O
the	O
subunit	O
interaction	O
subdomain	O
of	O
the	O
highly	O
conserved	O
DNA	O
binding-subunit	O
interaction	O
domain	O
(	O
DBD	O
)	O
of	O
NF-YA	B-protein
.	O
These	O
results	O
suggest	O
that	O
in	O
class	O
II+	O
mature	O
B-cells	O
NF-Y	B-protein
is	O
associated	O
with	O
the	O
protein	O
cofactor	O
,	O
PC4	B-protein
,	O
which	O
may	O
play	O
an	O
important	O
role	O
in	O
NF-Y-mediated	O
transcriptional	O
control	O
of	O
class	O
II	O
genes	O
.	O
Arrest	O
of	O
B	O
lymphocyte	O
terminal	O
differentiation	O
by	O
CD40	O
signaling	O
:	O
mechanism	O
for	O
lack	O
of	O
antibody-secreting	O
cells	O
in	O
germinal	O
centers	O
.	O
Despite	O
extensive	O
research	O
,	O
the	O
role	O
of	O
CD40	B-protein
signaling	O
in	O
B	O
cell	O
terminal	O
differentiation	O
remains	O
controversial	O
.	O
Here	O
we	O
show	O
that	O
CD40	O
engagement	O
arrests	O
B	O
cell	O
differentiation	O
prior	O
to	O
plasma	O
cell	O
formation	O
.	O
This	O
arrest	O
is	O
manifested	O
at	O
a	O
molecular	O
level	O
as	O
a	O
reduction	O
in	O
mRNA	O
levels	O
of	O
secretory	O
immunoglobulin	O
gene	O
products	O
such	O
as	O
mu	O
(	O
s	O
)	O
and	O
J	B-protein
chain	I-protein
as	O
well	O
as	O
the	O
loss	O
of	O
the	O
transcriptional	B-protein
regulator	I-protein
BLIMP-1	I-protein
.	O
Furthermore	O
,	O
the	O
inhibition	O
of	O
B	O
cell	O
differentiation	O
by	O
CD40	O
engagement	O
could	O
not	O
be	O
overcome	O
by	O
either	O
mitogens	O
or	O
cytokines	B-protein
,	O
but	O
could	O
be	O
reversed	O
by	O
antibodies	B-protein
that	O
interfere	O
with	O
the	O
CD40	B-protein
/	O
gp39	O
interaction	O
.	O
These	O
data	O
suggest	O
that	O
secretory	O
immunoglobulin	O
is	O
not	O
produced	O
by	O
B	O
cells	O
that	O
are	O
actively	O
engaged	O
by	O
gp39-expressing	O
T	O
cells	O
.	O
A	O
positively	O
charged	O
alpha-lipoic	O
acid	O
analogue	O
with	O
increased	O
cellular	O
uptake	O
and	O
more	O
potent	O
immunomodulatory	O
activity	O
.	O
alpha-Lipoic	O
acid	O
(	O
LA	O
)	O
is	O
taken	O
up	O
by	O
cells	O
and	O
reduced	O
to	O
its	O
potent	O
dithiol	O
form	O
,	O
dihydrolipoate	O
(	O
DHLA	O
)	O
,	O
much	O
of	O
which	O
is	O
rapidly	O
effluxed	O
out	O
from	O
cells	O
.	O
To	O
improve	O
retention	O
in	O
cells	O
,	O
the	O
LA	B-protein
molecule	I-protein
was	O
modified	O
to	O
confer	O
a	O
positive	O
charge	O
at	O
physiological	O
pH	O
.	O
N	O
,	O
N-dimethyl	O
,	O
N'-2-amidoethyl-lipoate	O
was	O
synthesized	O
.	O
The	O
protonated	O
form	O
of	O
the	O
new	O
molecule	O
is	O
referred	O
to	O
as	O
LA-Plus	O
.	O
The	O
uptake	O
of	O
LA-Plus	O
by	O
human	O
Wurzburg	O
T	O
cells	O
was	O
higher	O
compared	O
to	O
that	O
of	O
LA	O
.	O
Several-fold	O
higher	O
amounts	O
of	O
DHLA-Plus	O
,	O
the	O
corresponding	O
reduced	O
form	O
of	O
LA-Plus	O
,	O
were	O
detected	O
in	O
LA-Plus	O
treated	O
cells	O
compared	O
to	O
the	O
amount	O
of	O
DHLA	O
found	O
in	O
cells	O
treated	O
with	O
LA	O
.	O
At	O
100	O
microM	O
,	O
LA	O
did	O
not	O
but	O
LA-Plus	O
inhibited	O
H2O2	O
induced	O
NF-kappaB	B-protein
activation	O
and	O
NF-kappaB	B-protein
directed	O
IL-2	O
receptor	O
expression	O
.	O
Both	O
LA	O
and	O
LA-Plus	O
synergised	O
with	O
selenium	O
in	O
inhibiting	O
H2O2	O
induced	O
NF-kappaB	B-protein
activation	O
.	O
At	O
150	O
microM	O
LA-Plus	O
,	O
but	O
not	O
LA	O
,	O
inhibited	O
TNFalpha	B-protein
induced	O
NF-kappaB	B-protein
activation	O
.	O
At	O
5	O
microM	O
LA-Plus	O
,	O
but	O
not	O
LA	O
,	O
protected	O
against	O
both	O
spontaneous	O
and	O
etoposide	O
induced	O
apoptosis	O
in	O
rat	O
thymocytes	O
.	O
LA-Plus	O
is	O
thus	O
an	O
improved	O
form	O
of	O
LA	O
with	O
increased	O
therapeutic	O
potential	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Carrier	O
identification	O
in	O
X-linked	O
immunodeficiency	O
diseases	O
.	O
OBJECTIVE	O
:	O
Carrier	O
identification	O
in	O
X-linked	O
immunodeficiency	O
disorders	O
can	O
be	O
based	O
on	O
the	O
demonstration	O
of	O
non-random	O
X	O
inactivation	O
(	O
NRXI	O
)	O
in	O
affected	O
blood	O
cell	O
lineages	O
when	O
growth	O
is	O
impaired	O
in	O
cells	O
expressing	O
the	O
abnormal	O
gene	O
.	O
We	O
examined	O
the	O
utility	O
of	O
seeking	O
evidence	O
of	O
NRXI	O
to	O
test	O
the	O
carrier	O
status	O
of	O
women	O
in	O
families	O
affected	O
by	O
X-linked	O
severe	O
combined	O
immunodeficiency	O
(	O
XSCID	O
)	O
and	O
X-linked	O
hypogammaglobulinaemia	O
(	O
XLH	O
)	O
,	O
to	O
identify	O
as	O
carriers	O
the	O
mothers	O
of	O
boys	O
with	O
SCID	O
or	O
hypogammaglobulinaemia	O
whose	O
phenotype	O
suggested	O
X-linkage	O
and	O
to	O
infer	O
X-linkage	O
in	O
boys	O
with	O
SCID	O
or	O
hypogammaglobulinaemia	O
whose	O
disease	O
was	O
not	O
clearly	O
X-linked	O
on	O
the	O
basis	O
either	O
of	O
family	O
history	O
or	O
clinical	O
and	O
immunological	O
characteristics	O
.	O
METHODOLOGY	O
:	O
A	O
polymerase	O
chain	O
reaction-based	O
method	O
was	O
used	O
to	O
amplify	O
a	O
polymorphic	O
CAG	O
repeat	O
in	O
the	O
first	O
exon	O
of	O
the	O
androgen	O
receptor	O
gene	O
after	O
selective	O
digestion	O
of	O
the	O
active	O
X	O
chromosome	O
with	O
a	O
methylation-sensitive	B-protein
enzyme	I-protein
,	O
HpaII	O
to	O
distinguish	O
between	O
the	O
paternal	O
and	O
maternal	O
alleles	O
and	O
to	O
identify	O
their	O
methylation	O
status	O
.	O
RESULTS	O
:	O
Heterozygosity	O
was	O
found	O
in	O
24	O
of	O
31	O
female	O
subjects	O
(	O
77	O
%	O
)	O
.	O
As	O
anticipated	O
,	O
NRXI	O
could	O
be	O
demonstrated	O
in	O
all	O
lymphoid	O
cells	O
studied	O
from	O
obligate	O
carriers	O
of	O
XSCID	B-protein
and	O
an	O
obligate	O
carrier	O
of	O
XLH	O
but	O
not	O
on	O
a	O
carrier	O
of	O
X-linked	O
immunodeficiency	O
with	O
hyper-IgM	O
.	O
The	O
finding	O
of	O
NRXI	O
in	O
the	O
mother	O
of	O
a	O
boy	O
with	O
a	O
SCID	O
variant	O
showed	O
her	O
to	O
be	O
a	O
carrier	O
of	O
XSCID	O
and	O
establishes	O
that	O
her	O
son	O
has	O
XSCID	O
,	O
not	O
otherwise	O
evident	O
from	O
available	O
data	O
.	O
CONCLUSIONS	O
:	O
This	O
PCR	O
assay	O
provides	O
a	O
rapid	O
method	O
for	O
carrier	O
detection	O
of	O
X-linked	O
immunodeficiencies	O
,	O
and	O
has	O
allowed	O
us	O
to	O
expand	O
the	O
phenotype	O
of	O
XSCID	O
Leukocyte-endothelial	O
interaction	O
is	O
augmented	O
by	O
high	O
glucose	O
concentrations	O
and	O
hyperglycemia	O
in	O
a	O
NF-kB-dependent	O
fashion	O
.	O
We	O
addressed	O
the	O
role	O
of	O
hyperglycemia	O
in	O
leukocyte-endothelium	O
interaction	O
under	O
flow	O
conditions	O
by	O
exposing	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
for	O
24	O
h	O
to	O
normal	O
(	O
5	O
mM	O
)	O
,	O
high	O
concentration	O
of	O
glucose	O
(	O
30	O
mM	O
)	O
,	O
advanced	O
glycosylation	O
end	O
product-albumin	O
(	O
100	O
microg/ml	O
)	O
,	O
or	O
hyperglycemic	O
(	O
174-316	O
mg/dl	O
)	O
sera	O
from	O
patients	O
with	O
diabetes	O
and	O
abnormal	O
hemoglobin	O
A1c	O
(	O
8.1+/-1.4	O
%	O
)	O
.	O
At	O
the	O
end	O
of	O
incubation	O
endothelial	O
cells	O
were	O
perfused	O
with	O
total	O
leukocyte	O
suspension	O
in	O
a	O
parallel	O
plate	O
flow	O
chamber	O
under	O
laminar	O
flow	O
(	O
1.5	O
dyn/cm2	O
)	O
.	O
Rolling	O
and	O
adherent	O
cells	O
were	O
evaluated	O
by	O
digital	O
image	O
processing	O
.	O
Results	O
showed	O
that	O
30	O
mM	O
glucose	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
increased	O
the	O
number	O
of	O
adherent	O
leukocytes	O
to	O
endothelial	O
cells	O
in	O
respect	O
to	O
control	O
(	O
5	O
mM	O
glucose	O
;	O
151+/-19	O
versus	O
33+/-8	O
cells/mm2	O
)	O
.	O
A	O
similar	O
response	O
was	O
induced	O
by	O
endothelial	O
stimulation	O
with	O
IL-1beta	B-protein
,	O
here	O
used	O
as	O
positive	O
control	O
(	O
195+/-20	O
cells/mm2	O
)	O
.	O
The	O
number	O
of	O
rolling	O
cells	O
on	O
endothelial	O
surface	O
was	O
not	O
affected	O
by	O
high	O
glucose	O
level	O
.	O
Stable	O
adhesion	O
of	O
leukocytes	O
to	O
glucose-treated	O
as	O
well	O
as	O
to	O
IL-1beta-stimulated	O
endothelial	O
cells	O
was	O
preceded	O
by	O
short	O
interaction	O
of	O
leukocytes	O
with	O
the	O
endothelial	O
surface	O
.	O
The	O
distance	O
travelled	O
by	O
leukocytes	O
before	O
arrest	O
on	O
30	O
mM	O
glucose	O
,	O
or	O
on	O
IL-1beta-treated	O
endothelial	O
cells	O
,	O
was	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
higher	O
than	O
that	O
observed	O
for	O
leukocytes	O
adhering	O
on	O
control	O
endothelium	O
(	O
30	O
mM	O
glucose	O
:	O
76.7+/-3.5	O
;	O
IL1beta	O
:	O
69.7+/-4	O
versus	O
5	O
mM	O
glucose	O
:	O
21.5+/-5	O
microm	O
)	O
.	O
Functional	O
blocking	O
of	O
E-selectin	B-protein
,	O
intercellular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
on	O
endothelial	O
cells	O
with	O
the	O
corresponding	O
mouse	O
mAb	O
significantly	O
inhibited	O
glucose-induced	O
increase	O
in	O
leukocyte	O
adhesion	O
(	O
67+/-16	O
,	O
83+/-12	O
,	O
62+/-8	O
versus	O
144+/-21	O
cells/	O
mm2	O
)	O
.	O
Confocal	O
fluorescence	O
microscopy	O
studies	O
showed	O
that	O
30	O
mM	O
glucose	O
induced	O
an	O
increase	O
in	O
endothelial	O
surface	O
expression	O
of	O
E-selectin	B-protein
,	O
intercellular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
,	O
and	O
vascular	B-protein
cell	I-protein
adhesion	I-protein
molecule-1	I-protein
.	O
Electrophoretic	O
mobility	O
shift	O
assay	O
of	O
nuclear	O
extracts	O
of	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVEC	O
)	O
exposed	O
for	O
1	O
h	O
to	O
30	O
mM	O
glucose	O
revealed	O
an	O
intense	O
NF-kB	O
activation	O
.	O
Treatment	O
of	O
HUVEC	B-protein
exposed	O
to	O
high	O
glucose	O
with	O
the	O
NF-kB	O
inhibitors	O
pyrrolidinedithiocarbamate	O
(	O
100	O
microM	O
)	O
and	O
tosyl-phe-chloromethylketone	O
(	O
25	O
microM	O
)	O
significantly	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
leukocyte	O
adhesion	O
in	O
respect	O
to	O
HUVEC	O
treated	O
with	O
glucose	O
alone	O
.	O
A	O
significant	O
(	O
P	O
<	O
0.01	O
)	O
inhibitory	O
effect	O
on	O
glucose-induced	O
leukocyte	O
adhesion	O
was	O
observed	O
after	O
blocking	O
protein	B-protein
kinase	I-protein
C	I-protein
activity	O
with	O
staurosporine	O
(	O
5	O
nM	O
)	O
.	O
When	O
HUVEC	O
were	O
treated	O
with	O
specific	O
antisense	O
oligodesoxynucleotides	O
against	O
PKCalpha	B-protein
and	O
PKCepsilon	O
isoforms	O
before	O
the	O
addition	O
of	O
30	O
mM	O
glucose	O
,	O
a	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
reduction	O
in	O
the	O
adhesion	O
was	O
also	O
seen	O
.	O
Advanced	O
glycosylation	O
end	O
product-albumin	O
significantly	O
increased	O
the	O
number	O
of	O
adhering	O
leukocytes	O
in	O
respect	O
to	O
native	B-protein
albumin	I-protein
used	O
as	O
control	O
(	O
110+/-16	O
versus	O
66+/-7	O
,	O
P	O
<	O
0.01	O
)	O
.	O
Sera	O
from	O
diabetic	O
patients	O
significantly	O
(	O
P	O
<	O
0.01	O
)	O
enhanced	O
leukocyte	O
adhesion	O
as	O
compared	O
with	O
controls	O
,	O
despite	O
normal	O
levels	O
of	O
IL-1beta	B-protein
and	O
TNFalpha	B-protein
in	O
these	O
sera	O
.	O
These	O
data	O
indicate	O
that	O
high	O
glucose	O
concentration	O
and	O
hyperglycemia	O
promote	O
leukocyte	O
adhesion	O
to	O
the	O
endothelium	O
through	O
upregulation	O
of	O
cell	O
surface	O
expression	O
of	O
adhesive	B-protein
proteins	I-protein
,	O
possibly	O
depending	O
on	O
NF-kB	O
activation	O
.	O
Ikaros	B-protein
in	O
hemopoietic	O
lineage	O
determination	O
and	O
homeostasis	O
.	O
Studies	O
on	O
the	O
molecular	O
mechanisms	O
that	O
control	O
hemopoietic	O
differentiation	O
have	O
focused	O
on	O
signaling	O
cascades	O
and	O
nuclear	O
effectors	O
that	O
drive	O
this	O
complex	O
developmental	O
system	O
in	O
a	O
regulated	O
fashion	O
.	O
Here	O
we	O
review	O
the	O
role	O
of	O
Ikaros	B-protein
,	O
the	O
founding	O
member	O
of	O
a	O
unique	O
family	O
of	O
zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	O
this	O
developmental	O
process	O
.	O
Studies	O
on	O
an	O
Ikaros	B-protein
null	O
mutation	O
have	O
revealed	O
an	O
essential	O
role	O
for	O
this	O
factor	O
in	O
lymphoid	O
cell	O
fate	O
determination	O
and	O
at	O
subsequent	O
branch	O
points	O
of	O
the	O
T	O
cell	O
differentiation	O
pathway	O
.	O
Differences	O
in	O
the	O
phenotypes	O
of	O
a	O
null	O
and	O
a	O
dominant	O
negative	O
(	O
DN	O
)	O
Ikaros	O
mutation	O
provide	O
insight	O
into	O
a	O
regulatory	O
network	O
through	O
which	O
Ikaros	B-protein
proteins	I-protein
exert	O
their	O
effects	O
in	O
development	O
.	O
In	O
addition	O
a	O
comparative	O
analysis	O
of	O
the	O
hemopoietic	O
stem	O
cell	O
and	O
precursor	O
compartment	O
resulting	O
from	O
the	O
two	O
Ikaros	O
mutations	O
reveals	O
a	O
profound	O
yet	O
not	O
absolute	O
requirement	O
for	O
Ikaros	B-protein
Induction	O
of	O
early	B-protein
B	I-protein
cell	I-protein
factor	I-protein
(	O
EBF	O
)	O
and	O
multiple	O
B	O
lineage	O
genes	O
by	O
the	O
basic	O
helix-loop-helix	B-protein
transcription	I-protein
factor	I-protein
E12	I-protein
.	O
The	O
transcription	B-protein
factors	I-protein
encoded	O
by	O
the	O
E2A	O
and	O
early	O
B	O
cell	O
factor	O
(	O
EBF	O
)	O
genes	O
are	O
required	O
for	O
the	O
proper	O
development	O
of	O
B	O
lymphocytes	O
.	O
However	O
,	O
the	O
absence	O
of	O
B	O
lineage	O
cells	O
in	O
E2A-	O
and	O
EBF-deficient	O
mice	O
has	O
made	O
it	O
difficult	O
to	O
determine	O
the	O
function	O
or	O
relationship	O
between	O
these	O
proteins	O
.	O
We	O
report	O
the	O
identification	O
of	O
a	O
novel	O
model	O
system	O
in	O
which	O
the	O
role	O
of	O
E2A	B-protein
and	O
EBF	O
in	O
the	O
regulation	O
of	O
multiple	O
B	O
lineage	O
traits	O
can	O
be	O
studied	O
.	O
We	O
found	O
that	O
the	O
conversion	O
of	O
70Z/3	O
pre-B	O
lymphocytes	O
to	O
cells	O
with	O
a	O
macrophage-like	O
phenotype	O
is	O
associated	O
with	O
the	O
loss	O
of	O
E2A	B-protein
and	O
EBF	O
.	O
Moreover	O
,	O
we	O
show	O
that	O
ectopic	O
expression	O
of	O
the	O
E2A	O
protein	O
E12	O
in	O
this	O
macrophage	O
line	O
results	O
in	O
the	O
induction	O
of	O
many	O
B	O
lineage	O
genes	O
,	O
including	O
EBF	B-protein
,	O
IL7Ralpha	O
,	O
lambda5	O
,	O
and	O
Rag-1	O
,	O
and	O
the	O
ability	O
to	O
induce	O
kappa	O
light	O
chain	O
in	O
response	O
to	O
mitogen	O
.	O
Activation	O
of	O
EBF	B-protein
may	O
be	O
one	O
of	O
the	O
critical	O
functions	O
of	O
E12	O
in	O
regulating	O
the	O
B	O
lineage	O
phenotype	O
since	O
expression	O
of	O
EBF	B-protein
alone	O
leads	O
to	O
the	O
activation	O
of	O
a	O
subset	O
of	O
E12	O
-inducible	O
traits	O
.	O
Our	O
data	O
demonstrate	O
that	O
,	O
in	O
the	O
context	O
of	O
this	O
macrophage	O
line	O
,	O
E12	B-protein
induces	O
expression	O
of	O
EBF	B-protein
and	O
together	O
these	O
transcription	B-protein
factors	I-protein
coordinately	O
regulate	O
numerous	O
B	O
lineage-associated	O
genes	O
.	O
Activation-induced	O
down-regulation	O
of	O
retinoid	B-protein
receptor	I-protein
RXRalpha	B-protein
expression	O
in	O
human	O
T	O
lymphocytes	O
.	O
Role	O
of	O
cell	O
cycle	O
regulation	O
.	O
A	O
5.4-kilobase	O
mRNA	O
,	O
the	O
expression	O
of	O
which	O
is	O
down-regulated	O
after	O
treatment	O
of	O
human	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
with	O
various	O
T	O
cell-activating	O
agents	O
,	O
was	O
isolated	O
using	O
an	O
mRNA	O
differential	O
display	O
method	O
.	O
Nucleotide	O
sequence	O
analysis	O
identified	O
the	O
5	O
'	O
end	O
of	O
this	O
RNA	O
as	O
human	O
retinoid	O
receptor	O
RXRalpha	O
mRNA	O
.	O
Here	O
,	O
we	O
report	O
the	O
nucleotide	O
sequence	O
of	O
3.6	O
kilobases	O
of	O
this	O
RNA	O
,	O
which	O
represents	O
the	O
3	O
'	O
end	O
of	O
RXRalpha	O
mRNA	O
,	O
the	O
sequence	O
of	O
which	O
has	O
not	O
been	O
previously	O
described	O
.	O
Activated	O
PBMCs	O
also	O
expressed	O
lower	O
levels	O
of	O
RXRalpha	B-protein
protein	I-protein
,	O
and	O
a	O
DNA	O
binding	O
assay	O
showed	O
that	O
the	O
activation-induced	O
loss	O
of	O
RXRalpha	O
mRNA	O
and	O
protein	O
expression	O
correlated	O
with	O
the	O
loss	O
of	O
DNA	O
binding	O
activity	O
of	O
this	O
protein	O
.	O
We	O
present	O
evidence	O
that	O
the	O
transition	O
from	O
G0/G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
results	O
in	O
the	O
down-regulation	O
of	O
RXRalpha	B-protein
expression	O
and	O
that	O
cell	O
cycle	O
inhibitors	O
,	O
which	O
block	O
the	O
cells	O
in	O
G1	O
phase	O
,	O
prevent	O
this	O
down-regulation	O
.	O
The	O
decrease	O
in	O
the	O
levels	O
of	O
RXRalpha	O
mRNA	O
was	O
found	O
to	O
be	O
regulated	O
at	O
the	O
post-transcriptional	O
level	O
and	O
involved	O
new	O
protein	O
synthesis	O
.	O
These	O
observations	O
indicate	O
that	O
the	O
levels	O
of	O
RXRalpha	B-protein
expression	O
in	O
T	O
lymphocytes	O
are	O
coupled	O
to	O
cell	O
cycle	O
progression	O
,	O
and	O
there	O
is	O
tight	O
regulatory	O
control	O
of	O
RXRalpha	B-protein
expression	O
during	O
the	O
transition	O
from	O
G0/G1	O
to	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O
Epidemiology	O
and	O
pathogenesis	O
of	O
AIDS-related	O
lymphomas	O
.	O
Among	O
patients	O
with	O
congenital	O
and	O
acquired	O
immunodeficiencies	O
,	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHLs	O
)	O
are	O
the	O
most	O
common	O
tumors	O
of	O
the	O
immune	O
system	O
.	O
In	O
the	O
setting	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
,	O
as	O
many	O
as	O
10	O
%	O
to	O
20	O
%	O
of	O
people	O
ultimately	O
developed	O
NHLs	O
.	O
These	O
tumors	O
are	O
clinically	O
aggressive	O
,	O
frequently	O
involve	O
extranodal	O
sites	O
,	O
and	O
often	O
exhibit	O
unique	O
features	O
that	O
distinguish	O
them	O
from	O
NHL	O
arising	O
in	O
individuals	O
with	O
other	O
forms	O
of	O
immunosuppression	O
.	O
Important	O
in	O
the	O
development	O
of	O
HIV-associated	O
NHL	O
are	O
cytokines	B-protein
and	O
other	O
factors	O
that	O
induce	O
B-cell	O
proliferation	O
and	O
increase	O
the	O
likelihood	O
of	O
mutations	O
of	O
c-myc	O
,	O
bcl-6	O
,	O
and	O
other	O
tumor-suppressor	O
genes	O
with	O
carcinogenic	O
potential	O
.	O
Specific	O
forms	O
of	O
HIV-associated	O
NHL	O
are	O
linked	O
to	O
expression	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-latent	O
proteins	O
;	O
the	O
newly	O
described	O
DNA	O
virus	O
,	O
Karposi	O
's	O
sarcoma-associated	O
herpesvirus/human	O
herpesvirus-8	O
(	O
KSHV/HHV-8	O
)	O
;	O
and	O
perhaps	O
HIV	O
.	O
Elucidation	O
of	O
the	O
factors	O
that	O
contribute	O
to	O
the	O
high	O
incidence	O
of	O
NHL	O
among	O
patients	O
infected	O
with	O
HIV	O
provides	O
insights	O
into	O
important	O
elements	O
of	O
lymphomagenesis	O
.	O
Matrix	O
metalloproteinase	O
expression	O
in	O
human	O
breast	O
cancer	O
:	O
an	O
immunohistochemical	O
study	O
including	O
correlation	O
with	O
cathepsin	O
D	O
,	O
type	O
IV	O
collagen	O
,	O
laminin	O
,	O
fibronectin	O
,	O
EGFR	O
,	O
c-erbB-2	O
oncoprotein	O
,	O
p53	O
,	O
steroid	O
receptors	O
status	O
and	O
proliferative	O
indices	O
.	O
Matrix	O
metalloproteinase	O
s	O
(	O
MMPs	O
)	O
are	O
a	O
group	O
of	O
enzymes	O
thought	O
to	O
be	O
responsible	O
for	O
both	O
normal	O
connective	O
tissue	O
matrix	O
remodelling	O
and	O
accelerated	O
breakdown	O
associated	O
with	O
tumour	O
development	O
.	O
The	O
current	O
study	O
aimed	O
to	O
investigate	O
the	O
immunohistochemical	O
expression	O
of	O
matrix	O
metalloproteinase	O
3	O
(	O
MMP-3	O
,	O
stromelysin-1	O
)	O
in	O
correlation	O
with	O
the	O
expression	O
of	O
Basement	O
Membrane	O
(	O
BM	O
)	O
antigen	O
(	O
type	O
IV	O
collagen	O
,	O
laminin	O
)	O
,	O
fibronectin	O
,	O
cathepsin	O
D	O
,	O
p53	O
,	O
c-erbB-2	O
,	O
proliferative	O
activity	O
(	O
Ki-67	O
,	O
PCNA	O
)	O
,	O
steroid	B-protein
receptor	I-protein
content	O
as	O
well	O
as	O
to	O
the	O
other	O
conventional	O
clinicopathological	O
parameters	O
in	O
breast	O
cancer	O
.	O
This	O
study	O
was	O
performed	O
on	O
a	O
series	O
of	O
frozen	O
and	O
paraffin	O
sections	O
from	O
84	O
breast	O
cancer	O
specimens	O
by	O
immunohistochemistry	O
using	O
the	O
monoclonal	B-protein
antibody	I-protein
MMP-3	I-protein
(	O
Ab-1	O
)	O
.	O
Stromelysin-1	O
(	O
ST1	O
)	O
was	O
observed	O
in	O
about	O
10	O
%	O
of	O
epithelial	O
cells	O
in	O
the	O
control	O
groups	O
(	O
cases	O
of	O
fibrocystic	O
and	O
benign	O
proliferative	O
breast	O
disease	O
)	O
,	O
while	O
expression	O
(	O
>	O
10	O
%	O
of	O
expression	O
)	O
was	O
detected	O
in	O
89.7	O
%	O
of	O
tumours	O
.	O
The	O
expression	O
of	O
ST1	O
in	O
carcinoma	O
cells	O
was	O
strongly	O
associated	O
with	O
its	O
presence	O
in	O
the	O
stroma	O
(	O
p	O
<	O
0.001	O
)	O
.	O
A	O
significantly	O
positive	O
correlation	O
was	O
found	O
between	O
ST1	O
expression	O
,	O
and	O
p53	O
tumour	O
suppressor	O
gene	O
product	O
(	O
p	O
=	O
0.004	O
)	O
,	O
and	O
a	O
relationship	O
with	O
c-erbB-2	B-protein
protein	I-protein
and	I-protein
progesterone	I-protein
receptor	I-protein
status	O
was	O
also	O
indicated	O
.	O
These	O
findings	O
suggest	O
that	O
ST1	O
expression	O
in	O
breast	O
cancer	O
tissue	O
is	O
irrespective	O
of	O
the	O
expression	O
of	O
the	O
extracellular	O
matrix	O
component	O
,	O
the	O
proteolytic	B-protein
enzyme	I-protein
cathepsin	I-protein
D	I-protein
and	O
the	O
growth	O
fraction	O
of	O
the	O
tumour	O
,	O
and	O
that	O
it	O
could	O
be	O
a	O
potential	O
new	O
prognostic	O
marker	O
in	O
breast	O
cancer	O
.	O
Use	O
of	O
transfected	O
liver	O
cells	O
to	O
evaluate	O
potential	O
mechanisms	O
of	O
alcohol-induced	O
liver	O
injury	O
[	O
see	O
comments	O
]	O
There	O
is	O
increased	O
activity	O
of	O
the	O
proinflammatory	B-protein
cytokine	I-protein
,	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
in	O
alcoholic	O
liver	O
disease	O
(	O
ALD	O
)	O
.	O
Hepatic	O
neutrophil	O
infiltration	O
is	O
a	O
principal	O
injurious	O
manifestation	O
of	O
ALD	O
.	O
TNF	B-protein
can	O
induce	O
cellular	O
oxidative	O
injury	O
directly	O
,	O
and	O
indirectly	O
by	O
inducing	O
neutrophil	O
chemotactic	O
factor	O
(	O
IL-8	B-protein
)	O
production	O
by	O
hepatocytes	O
.	O
IL-8	O
activates	O
and	O
chemotactically	O
attracts	O
neutrophils	O
to	O
the	O
liver	O
where	O
they	O
release	O
oxidizing	O
substances	O
.	O
Patients	O
with	O
ALD	O
also	O
have	O
decreased	O
protective	O
factors	O
for	O
cellular	O
oxidative	O
injury	O
.	O
Manganous	O
superoxide	O
dismutase	O
(	O
MnSOD	O
)	O
is	O
an	O
antioxidant	O
protective	O
factor	O
.	O
The	O
objectives	O
of	O
these	O
studies	O
were	O
to	O
investigate	O
mechanisms	O
for	O
induction	O
of	O
an	O
injurious	O
factor	O
(	O
IL-8	B-protein
)	O
and	O
a	O
protective	O
factor	O
(	O
MnSOD	O
)	O
in	O
the	O
HepG2	O
human	O
hepatoma	O
cell	O
line	O
.	O
In	O
the	O
first	O
set	O
of	O
experiments	O
,	O
IL-8	O
gene	O
reporter	O
constructs	O
were	O
used	O
to	O
transiently	O
transfect	O
a	O
derivative	O
(	O
MVh2E1-9	O
)	O
of	O
the	O
HepG2	O
cell	O
line	O
which	O
expresses	O
P-4502E1	O
and	O
metabolizes	O
ethanol	O
.	O
Inactivation	O
of	O
the	O
NF-kappaB	B-protein
and	O
3'NF-IL-6	O
DNA	O
binding	O
sites	O
decreased	O
IL-8	O
gene	O
transcriptional	O
activation	O
in	O
response	O
to	O
TNF	O
while	O
inactivation	O
of	O
the	O
5'NF-IL-6	O
binding	O
site	O
increased	O
IL-8	O
gene	O
transcriptional	O
activity	O
in	O
response	O
to	O
TNF	B-protein
.	O
This	O
system	O
may	O
be	O
useful	O
to	O
assess	O
the	O
effects	O
of	O
ethanol	O
on	O
TNF	B-protein
-induced	O
hepatocyte	O
IL-8	O
production	O
.	O
In	O
the	O
second	O
set	O
of	O
experiments	O
,	O
HepG2	O
cells	O
were	O
cultured	O
in	O
25	O
to	O
100	O
mmol	O
concentrations	O
of	O
ethanol	O
.	O
Both	O
TNF	O
and	O
ethanol	O
increased	O
HepG2	O
cell	O
MnSOD	O
activity	O
in	O
short-term	O
(	O
72	O
hr	O
)	O
cultures	O
with	O
ethanol	O
.	O
However	O
,	O
after	O
long-term	O
(	O
10	O
weeks	O
)	O
culture	O
with	O
ethanol	O
,	O
there	O
was	O
no	O
induction	O
of	O
MnSOD	O
by	O
ethanol	O
and	O
there	O
was	O
a	O
diminished	O
induction	O
of	O
MnSOD	O
in	O
response	O
to	O
TNF	B-protein
.	O
Further	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
effect	O
of	O
this	O
diminished	O
induction	O
of	O
MnSOD	O
with	O
chronic	O
ethanol	O
culture	O
on	O
HepG2	O
cell	O
susceptibility	O
to	O
TNF	B-protein
cytotoxicity	I-protein
.	O
We	O
conclude	O
that	O
transfected	O
liver	O
cell	O
lines	O
can	O
be	O
used	O
to	O
evaluate	O
mechanisms	O
for	O
increased	O
injurious	B-protein
factors	I-protein
and	O
decreased	O
protective	O
factors	O
in	O
alcoholic	O
liver	O
injury	O
.	O
Tissue	O
factor	O
transcription	O
driven	O
by	O
Egr-1	O
is	O
a	O
critical	O
mechanism	O
of	O
murine	O
pulmonary	O
fibrin	O
deposition	O
in	O
hypoxia	O
.	O
Local	O
hypoxemia	O
and	O
stasis	O
trigger	O
thrombosis	O
.	O
We	O
have	O
demonstrated	O
previously	O
that	O
in	O
a	O
murine	O
model	O
of	O
normobaric	O
hypoxia	O
pulmonary	O
fibrin	O
deposition	O
is	O
a	O
result	O
of	O
expression	O
of	O
tissue	B-protein
factor	I-protein
,	O
especially	O
in	O
oxygen-deprived	O
mononuclear	O
phagocytes	O
(	O
MPs	O
)	O
.	O
We	O
now	O
show	O
that	O
transcription	B-protein
factor	I-protein
early-growth-response	O
gene	O
product	O
(	O
Egr-1	O
)	O
is	O
rapidly	O
activated	O
in	O
hypoxia	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
is	O
responsible	O
for	O
transcription	O
and	O
expression	O
of	O
tissue	B-protein
factor	I-protein
in	O
hypoxic	O
lung	O
.	O
MPs	O
and	O
HeLa	O
cells	O
subjected	O
to	O
hypoxia	O
(	O
pO2	O
approximately	O
13	O
torr	O
)	O
had	O
increased	O
levels	O
of	O
tissue	O
factor	O
transcripts	O
(	O
approximately	O
18-fold	O
)	O
and	O
an	O
increased	O
rate	O
of	O
transcription	O
(	O
approximately	O
15-fold	O
)	O
,	O
based	O
on	O
nuclear	O
run-on	O
analysis	O
.	O
Gel-shift	O
analysis	O
of	O
nuclear	O
extracts	O
from	O
hypoxic	O
MPs	O
and	O
HeLa	O
cells	O
demonstrated	O
increased	O
DNA-binding	O
activity	O
at	O
the	O
serum	O
response	O
region	O
(	O
SRR	O
;	O
-111/+14	O
bp	O
)	O
of	O
the	O
tissue	O
factor	O
promoter	O
at	O
Egr-1	O
motifs	O
.	O
Using	O
32P-labeled	O
Egr	O
consensus	O
oligonucleotide	O
,	O
we	O
observed	O
induction	O
of	O
DNA-binding	O
activity	O
in	O
nuclear	O
extracts	O
from	O
hypoxic	O
lung	O
and	O
HeLa	O
cells	O
because	O
of	O
activation	O
of	O
Egr-1	O
,	O
by	O
means	O
of	O
supershift	O
analysis	O
.	O
Transient	O
transfection	O
of	O
HeLa	O
cells	O
with	O
chimeric	O
plasmids	O
containing	O
wild-type	O
or	O
mutant	O
SRR	O
from	O
the	O
tissue	O
factor	O
promoter	O
showed	O
that	O
intact	O
Sp1	O
sites	O
are	O
necessary	O
for	O
basal	O
promoter	O
activity	O
,	O
whereas	O
the	O
integrity	O
of	O
Egr-1	O
sites	O
was	O
required	O
for	O
hypoxia-enhanced	O
expression	O
.	O
A	O
central	O
role	O
for	O
Egr-1	O
in	O
hypoxia-mediated	O
tissue	O
factor	O
expression	O
was	O
confirmed	O
by	O
experiments	O
with	O
homozygous	O
Egr-1	O
null	O
mice	O
;	O
wild-type	O
mice	O
subjected	O
to	O
oxygen	O
deprivation	O
expressed	O
tissue	B-protein
factor	I-protein
and	O
showed	O
fibrin	O
deposition	O
,	O
but	O
hypoxic	O
homozygous	O
Egr-1	O
null	O
mice	O
displayed	O
neither	O
tissue	B-protein
factor	I-protein
nor	O
fibrin	O
.	O
These	O
data	O
delineate	O
a	O
novel	O
biology	O
for	O
hypoxia-induced	O
fibrin	O
deposition	O
,	O
in	O
which	O
oxygen	O
deprivation-induced	O
activation	O
of	O
Egr-1	O
,	O
resulting	O
in	O
expression	O
of	O
tissue	B-protein
factor	I-protein
,	O
has	O
an	O
unexpected	O
and	O
central	O
role	O
.	O
Kinetics	O
of	O
cytokine	B-protein
and	O
NFAT	O
gene	O
expression	O
in	O
human	O
interleukin-2-dependent	O
T	O
lymphoblasts	O
stimulated	O
via	O
T-cell	B-protein
receptor	I-protein
.	O
T	O
cells	O
respond	O
to	O
mitogenic	O
or	O
antigenic	O
stimulation	O
by	O
proliferation	O
and	O
by	O
turning	O
on	O
cytokine	O
gene	O
expression	O
.	O
Here	O
we	O
have	O
analysed	O
the	O
kinetics	O
and	O
nature	O
of	O
cytokine	O
production	O
in	O
human	O
peripheral	O
blood-derived	O
T	O
lymphoblasts	O
stimulated	O
with	O
anti-CD3	B-protein
antibodies	I-protein
or	O
Lens	O
culinaris	O
lectin	O
(	O
LCL	O
)	O
.	O
T	O
cells	O
were	O
purified	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMC	O
)	O
and	O
primarily	O
activated	O
with	O
anti-CD3	B-protein
antibodies	I-protein
and	O
cultured	O
in	O
the	O
presence	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
.	O
Anti-CD3-restimulated	O
T	O
cells	O
(	O
mainly	O
CD8+	O
)	O
produced	O
IL-2	B-protein
,	O
interferon-gamma	B-protein
(	O
IFN-gamma	B-protein
)	O
and	O
tumour	B-protein
necrosis	I-protein
factor-alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
and	O
low	O
levels	O
of	O
IL-4	B-protein
and	O
IL-10	B-protein
transcripts	I-protein
and	I-protein
proteins	I-protein
.	O
No	O
IL-6	O
gene	O
expression	O
was	O
observed	O
.	O
In	O
LCL-stimulated	O
cells	O
the	O
cytokine	O
production	O
pattern	O
was	O
very	O
similar	O
.	O
Steady-state	O
mRNA	O
levels	O
of	O
IL-2	B-protein
,	O
IL-10	B-protein
and	O
IFN-gamma	B-protein
peaked	O
at	O
3	O
hr	O
after	O
anti-CD3	O
stimulation	O
and	O
declined	O
rapidly	O
thereafter	O
.	O
The	O
kinetics	O
of	O
TNF-alpha	O
mRNA	O
expression	O
was	O
faster	O
,	O
being	O
at	O
its	O
peak	O
level	O
1	O
hr	O
after	O
stimulation	O
.	O
Anti-CD3-stimulated	O
IL-2	O
gene	O
expression	O
was	O
down-regulated	O
by	O
protein	O
synthesis	O
inhibitor	O
,	O
whereas	O
IL-10	B-protein
,	O
IFN-gamma	B-protein
and	O
TNF-alpha	O
genes	O
were	O
readily	O
induced	O
independent	O
of	O
ongoing	O
protein	O
synthesis	O
.	O
T-cell	O
receptor	O
stimulation	O
also	O
induced	O
a	O
very	O
rapid	O
expression	O
of	O
c-jun	B-protein
,	O
c-fos	B-protein
and	O
NFATc1	B-protein
(	O
NFATc	B-protein
)	O
genes	O
,	O
the	O
gene	O
products	O
of	O
which	O
are	O
involved	O
in	O
cytokine	O
gene	O
expression	O
.	O
In	O
conclusion	O
,	O
the	O
cytokines	B-protein
synthesized	O
by	O
IL-2-dependent	O
T	O
cells	O
were	O
predominantly	O
IL-2	O
,	O
IFN-gamma	B-protein
and	O
TNF-alpha	B-protein
.	O
An	O
animal	O
model	O
to	O
study	O
local	O
oxidation	O
of	O
LDL	B-protein
and	O
its	O
biological	O
effects	O
in	O
the	O
arterial	O
wall	O
.	O
Oxidized	O
LDL	O
(	O
oxLDL	B-protein
)	O
is	O
present	O
in	O
atherosclerotic	O
lesions	O
and	O
is	O
believed	O
to	O
play	O
a	O
key	O
role	O
in	O
atherogenesis	O
.	O
Mainly	O
on	O
the	O
basis	O
of	O
cell	O
culture	O
studies	O
,	O
oxLDL	B-protein
has	O
been	O
shown	O
to	O
produce	O
many	O
biological	O
effects	O
that	O
influence	O
the	O
atherosclerotic	O
process	O
.	O
To	O
study	O
LDL	O
oxidation	O
in	O
vivo	O
,	O
we	O
have	O
established	O
a	O
model	O
in	O
which	O
Sprague-Dawley	O
rats	O
are	O
given	O
a	O
single	O
injection	O
of	O
unmodified	O
human	O
LDL	O
(	O
>	O
or	O
=	O
4	O
mg/kg	O
body	O
weight	O
)	O
.	O
Within	O
6	O
hours	O
,	O
an	O
accumulation	O
of	O
apolipoprotein	O
B	O
and	O
epitopes	O
present	O
on	O
oxLDL	B-protein
are	O
detected	O
in	O
the	O
arterial	O
endothelium	O
and	O
media	O
.	O
The	O
presence	O
of	O
oxLDL	B-protein
is	O
associated	O
with	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
nuclear	I-protein
factor-kappaB	I-protein
in	O
the	O
endothelium	O
as	O
well	O
as	O
endothelial	O
expression	O
of	O
intercellular	B-protein
adhesion	I-protein
molecule-1	I-protein
.	O
Injection	O
of	O
LDL	B-protein
enriched	O
with	O
the	O
antioxidant	O
probucol	O
resulted	O
in	O
arterial	O
accumulation	O
of	O
apolipoprotein	O
B	O
,	O
but	O
the	O
expression	O
of	O
oxLDL-specific	O
epitopes	O
was	O
reduced	O
at	O
24	O
hours	O
.	O
Thus	O
,	O
this	O
simple	O
model	O
has	O
the	O
potential	O
to	O
analyze	O
the	O
mechanisms	O
behind	O
and	O
biological	O
effects	O
of	O
LDL	O
oxidation	O
in	O
vivo	O
.	O
Molecular	O
mechanisms	O
of	O
promoter	O
regulation	O
of	O
the	O
gp34	O
gene	O
that	O
is	O
trans-activated	O
by	O
an	O
oncoprotein	B-protein
Tax	I-protein
of	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
.	O
We	O
investigated	O
the	O
molecular	O
mechanism	O
of	O
transcriptional	O
activation	O
of	O
the	O
gp34	O
gene	O
by	O
the	O
Tax	B-protein
oncoprotein	O
of	O
human	O
T	O
cell	O
leukemia	O
virus	O
type	O
I	O
(	O
HTLV-I	O
)	O
.	O
gp34	B-protein
is	O
a	O
type	B-protein
II	I-protein
transmembrane	I-protein
molecule	I-protein
belonging	O
to	O
the	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
family	I-protein
and	O
is	O
constitutively	O
expressed	O
on	O
HTLV-I-producing	O
cells	O
but	O
not	O
normal	O
resting	O
T	O
cells	O
.	O
The	O
transcriptional	O
regulatory	O
region	O
of	O
the	O
gp34	O
gene	O
was	O
activated	O
by	O
HTLV-I	B-protein
Tax	I-protein
in	O
the	O
human	O
T	O
cell	O
line	O
Jurkat	O
,	O
in	O
which	O
endogenous	O
gp34	B-protein
is	O
induced	O
by	O
Tax	B-protein
.	O
Sequence	O
analysis	O
demonstrated	O
that	O
two	O
NF-kappaB-like	O
elements	O
(	O
1	O
and	O
2	O
)	O
were	O
present	O
in	O
the	O
regulatory	O
region	O
.	O
Both	O
NF-kappaB-like	O
elements	O
were	O
able	O
to	O
bind	O
to	O
NF-kappaB	B-protein
or	O
its	O
related	O
factor	O
(	O
s	O
)	O
in	O
a	O
Tax	B-protein
-dependent	O
manner	O
.	O
Chloramphenicol	O
acetyltransferase	O
assays	O
indicated	O
that	O
NF-kappaB-like	O
element	O
1	O
was	O
Tax	O
-responsive	O
,	O
although	O
the	O
activity	O
was	O
lower	O
than	O
that	O
the	O
native	O
promoter	O
.	O
NF-kappaB	B-protein
-like	I-protein
element	I-protein
2	I-protein
elevated	O
promoter	O
activity	O
when	O
combined	O
with	O
NF-kappaB-like	O
element	O
1	O
,	O
indicating	O
cooperative	O
function	O
of	O
the	O
elements	O
for	O
maximum	O
promoter	O
function	O
.	O
Unlike	O
typical	O
NF-kappaB	O
elements	O
,	O
the	O
NF-kappaB-like	O
elements	O
in	O
gp34	O
were	O
not	O
activated	O
by	O
treatment	O
of	O
Jurkat	O
cells	O
with	O
phorbol	O
ester	O
despite	O
induction	O
of	O
the	O
NF-kappaB	B-protein
-like	O
binding	O
activity	O
.	O
Chloramphenicol	O
acetyltransferase	O
reporter	O
assays	O
using	O
the	O
region	O
upstream	O
of	O
the	O
NF-kappaB-like	O
elements	O
identified	O
an	O
upstream	O
region	O
that	O
reduced	O
transcription	O
from	O
cognate	O
and	O
noncognate	O
core	O
promoters	O
in	O
a	O
Tax-independent	O
manner	O
.	O
Our	O
results	O
imply	O
complex	O
regulation	O
of	O
expression	O
of	O
the	O
gp34	O
gene	O
and	O
suggest	O
implication	O
of	O
gp34	B-protein
in	O
proliferation	O
of	O
HTLV-I	O
infected	O
T	O
cells	O
.	O
beta-Amyloid	O
fibrils	O
activate	O
parallel	O
mitogen-activated	O
protein	O
kinase	O
pathways	O
in	O
microglia	O
and	O
THP1	O
monocytes	O
.	O
The	O
senile	O
plaques	O
of	O
Alzheimer	O
's	O
disease	O
are	O
foci	O
of	O
local	O
inflammatory	O
responses	O
,	O
as	O
evidenced	O
by	O
the	O
presence	O
of	O
acute	B-protein
phase	I-protein
proteins	I-protein
and	O
oxidative	O
damage	O
.	O
Fibrillar	O
forms	O
of	O
beta-amyloid	O
(	O
Abeta	O
)	O
,	O
which	O
are	O
the	O
primary	O
constituents	O
of	O
senile	O
plaques	O
,	O
have	O
been	O
shown	O
to	O
activate	O
tyrosine	O
kinase-dependent	O
signal	O
transduction	O
cascades	O
,	O
resulting	O
in	O
inflammatory	O
responses	O
in	O
microglia	O
.	O
However	O
,	O
the	O
downstream	O
signaling	O
pathways	O
mediating	O
Abeta	O
-induced	O
inflammatory	O
events	O
are	O
not	O
well	O
characterized	O
.	O
We	O
report	O
that	O
exposure	O
of	O
primary	O
rat	O
microglia	O
and	O
human	O
THP1	O
monocytes	O
to	O
fibrillar	O
Abeta	O
results	O
in	O
the	O
tyrosine	B-protein
kinase	I-protein
-dependent	O
activation	O
of	O
two	O
parallel	O
signal	O
transduction	O
cascades	O
involving	O
members	O
of	O
the	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
superfamily	O
.	O
Abeta	O
stimulated	O
the	O
rapid	O
,	O
transient	O
activation	O
of	O
extracellular	B-protein
signal-regulated	I-protein
kinase	I-protein
1	I-protein
(	O
ERK1	B-protein
)	O
and	O
ERK2	B-protein
in	O
microglia	O
and	O
ERK2	B-protein
in	O
THP1	O
monocytes	O
.	O
A	O
second	O
superfamily	O
member	O
,	O
p38	B-protein
MAPK	I-protein
,	O
was	O
also	O
activated	O
with	O
similar	O
kinetics	O
.	O
Scavenger	B-protein
receptor	I-protein
and	I-protein
receptor	I-protein
for	O
advanced	O
glycated	O
end	O
products	O
(	O
RAGE	B-protein
)	O
ligands	O
failed	O
to	O
activate	O
ERK	B-protein
and	O
p38	B-protein
MAPK	I-protein
in	O
the	O
absence	O
of	O
significant	O
increases	O
in	O
protein	O
tyrosine	O
phosphorylation	O
,	O
demonstrating	O
that	O
scavenger	B-protein
receptors	I-protein
and	O
RAGE	B-protein
are	O
not	O
linked	O
to	O
these	O
pathways	O
.	O
Importantly	O
,	O
the	O
stress-activated	B-protein
protein	I-protein
kinases	I-protein
(	O
SAPKs	O
)	O
were	O
not	O
significantly	O
activated	O
in	O
response	O
to	O
Abeta	O
.	O
Downstream	O
effectors	O
of	O
the	O
MAPK	B-protein
signal	O
transduction	O
cascades	O
include	O
MAPKAP	B-protein
kinases	I-protein
,	O
such	O
as	O
RSK1	B-protein
and	O
RSK2	O
,	O
as	O
well	O
as	O
transcription	B-protein
factors	I-protein
.	O
Exposure	O
of	O
microglia	O
and	O
THP1	O
monocytes	O
to	O
Abeta	O
resulted	O
in	O
the	O
activation	O
of	O
RSK1	B-protein
and	O
RSK2	B-protein
and	O
phosphorylation	O
of	O
cAMP	B-protein
response	I-protein
element-binding	I-protein
protein	I-protein
at	O
Ser133	O
,	O
providing	O
a	O
mechanism	O
for	O
Abeta	B-protein
-induced	O
changes	O
in	O
gene	O
expression	O
Regulation	O
of	O
cellular	O
retinoic	O
acid	O
binding	O
protein	O
(	O
CRABP	B-protein
II	I-protein
)	O
during	O
human	O
monocyte	O
differentiation	O
in	O
vitro	O
.	O
Cellular	O
retinoic	B-protein
acid	I-protein
binding	I-protein
proteins	I-protein
(	O
CRABP	O
)	O
are	O
low	O
molecular	O
weight	O
proteins	O
whose	O
precise	O
function	O
remains	O
unknown	O
.	O
They	O
bind	O
retinoids	O
and	O
may	O
thereby	O
modulate	O
the	O
intracellular	O
steady-state	O
concentration	O
of	O
retinoids	O
.	O
Whereas	O
CRABP	B-protein
I	I-protein
is	O
ubiquitously	O
expressed	O
,	O
CRABP	B-protein
II	I-protein
is	O
mainly	O
detected	O
in	O
various	O
cell	O
types	O
of	O
the	O
skin	O
.	O
By	O
representative	O
difference	O
analysis	O
we	O
found	O
that	O
CRABP	B-protein
II	I-protein
is	O
also	O
strongly	O
expressed	O
in	O
human	O
monocyte-derived	O
macrophages	O
(	O
MAC	O
)	O
but	O
not	O
in	O
freshly	O
isolated	O
monocytes	O
(	O
MO	O
)	O
.	O
The	O
CRABP	O
II	O
mRNA	O
was	O
gradually	O
upregulated	O
during	O
differentiation	O
from	O
MO	O
to	O
MAC	O
in	O
the	O
presence	O
of	O
2	O
%	O
serum	O
.	O
Adherence	O
,	O
which	O
is	O
important	O
for	O
MO	O
differentiation	O
,	O
induced	O
CRABP	O
II	O
expression	O
,	O
but	O
the	O
addition	O
of	O
10	O
(	O
-7	O
)	O
M	O
retinoic	O
acid	O
inhibited	O
the	O
upregulation	O
of	O
CRABP	B-protein
II	I-protein
expression	O
during	O
MO/MAC	O
differentiation	O
.	O
As	O
MO	B-protein
can	O
differentiate	O
along	O
the	O
classical	O
pathway	O
not	O
only	O
to	O
MAC	O
but	O
also	O
to	O
dendritic	O
cells	O
we	O
analyzed	O
the	O
expression	O
of	O
CRABP	B-protein
II	I-protein
in	O
MO-derived	O
dendritic	O
cells	O
cultured	O
with	O
10	O
%	O
FCS	O
,	O
IL-4	B-protein
,	O
and	O
GM-CSF	B-protein
.	O
In	O
contrast	O
to	O
MAC	O
,	O
MO-derived	O
dendritic	O
cells	O
showed	O
an	O
extremely	O
low	O
expression	O
of	O
CRABP	B-protein
II	I-protein
.	O
From	O
these	O
results	O
we	O
conclude	O
(	O
1	O
)	O
that	O
the	O
availability	O
and	O
the	O
metabolism	O
of	O
retinoids	O
may	O
be	O
different	O
in	O
MAC	O
compared	O
to	O
MO	O
and	O
dendritic	O
cells	O
and	O
(	O
2	O
)	O
that	O
this	O
may	O
influence	O
differentiation	O
and	O
activation	O
of	O
those	O
cells	O
.	O
Transcription	B-protein
factor	I-protein
B-cell-specific	I-protein
activator	I-protein
protein	I-protein
(	O
BSAP	O
)	O
is	O
differentially	O
expressed	O
in	O
B	O
cells	O
and	O
in	O
subsets	O
of	O
B-cell	O
lymphomas	O
.	O
The	O
paired	O
box	O
containing	O
gene	O
PAX-5	O
encodes	O
the	O
transcription	B-protein
factor	I-protein
BSAP	I-protein
(	O
B-cell-specific	B-protein
activator	I-protein
protein	I-protein
)	O
,	O
which	O
plays	O
a	O
key	O
role	O
in	O
B-lymphocyte	O
development	O
.	O
Despite	O
its	O
known	O
involvement	O
in	O
a	O
rare	O
subtype	O
of	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
,	O
a	O
detailed	O
examination	O
of	O
BSAP	O
expression	O
in	O
NHL	O
has	O
not	O
been	O
previously	O
reported	O
.	O
In	O
this	O
study	O
,	O
we	O
analyzed	O
normal	O
and	O
malignant	O
lymphoid	O
tissues	O
and	O
cell	O
lines	O
,	O
including	O
102	O
cases	O
of	O
B-cell	O
NHL	O
,	O
23	O
cases	O
of	O
T-	O
and	O
null-cell	O
NHL	O
,	O
and	O
18	O
cases	O
of	O
Hodgkin	O
's	O
disease	O
.	O
Normal	O
lymphoid	O
tissues	O
showed	O
strong	O
nuclear	O
BSAP	O
expression	O
in	O
mantle	O
zone	O
B	O
cells	O
,	O
less	O
intense	O
reactivity	O
in	O
follicular	O
center	O
B	O
cells	O
,	O
and	O
no	O
expression	O
in	O
cells	O
of	O
the	O
T-cell-rich	O
zones	O
.	O
Monocytoid	O
B	O
cells	O
showed	O
weak	O
expression	O
,	O
whereas	O
plasma	O
cells	O
and	O
extrafollicular	O
large	O
transformed	O
B	O
cells	O
were	O
negative	O
.	O
Of	O
the	O
102	O
B-cell	O
NHLs	O
,	O
83	O
(	O
81	O
%	O
)	O
demonstrated	O
BSAP	O
expression	O
.	O
All	O
of	O
the	O
13	O
(	O
100	O
%	O
)	O
B-cell	O
chronic	O
lymphocytic	O
leukemias	O
(	O
B-CLLs	O
)	O
,	O
21	O
of	O
(	O
100	O
%	O
)	O
mantle	O
cells	O
(	O
MCLs	O
)	O
,	O
and	O
20	O
of	O
21	O
(	O
95	O
%	O
)	O
follicular	O
lymphomas	O
(	O
FLs	O
)	O
were	O
positive	O
.	O
Moderate	O
staining	O
intensities	O
were	O
found	O
in	O
most	O
B-CLL	O
and	O
FL	O
cases	O
,	O
whereas	O
most	O
MCLs	O
showed	O
strong	O
reactions	O
,	O
paralleling	O
the	O
strong	O
reactivity	O
of	O
nonmalignant	O
mantle	O
cells	O
.	O
Eight	O
of	O
12	O
(	O
67	O
%	O
)	O
marginal	O
zone	O
lymphoma	O
cases	O
showed	O
negative	O
or	O
low	O
BSAP	O
levels	O
,	O
and	O
17	O
of	O
24	O
(	O
71	O
%	O
)	O
large	O
B-cell	O
lymphomas	O
displayed	O
moderate	O
to	O
strong	O
expression	O
.	O
None	O
of	O
the	O
23	O
T-	O
and	O
null-cell	O
lymphomas	O
reacted	O
with	O
the	O
BSAP	O
antisera	O
,	O
whereas	O
in	O
Hodgkin	O
's	O
disease	O
,	O
2	O
of	O
4	O
(	O
50	O
%	O
)	O
nodular	O
lymphocytic	O
predominance	O
and	O
5	O
of	O
14	O
(	O
36	O
%	O
)	O
classical	O
cases	O
showed	O
weak	O
nuclear	O
or	O
nucleolar	O
BSAP	O
reactions	O
in	O
a	O
fraction	O
of	O
the	O
tumor	O
cells	O
.	O
Western	O
blot	O
analysis	O
showed	O
a	O
52-kD	O
BSAP	O
band	O
in	O
B-cell	O
lines	O
,	O
but	O
not	O
in	O
non-B-cell	O
or	O
plasma	O
cell	O
lines	O
.	O
We	O
conclude	O
that	O
BSAP	O
expression	O
is	O
largely	O
restricted	O
to	O
lymphomas	O
of	O
B-cell	O
lineage	O
and	O
that	O
BSAP	O
expression	O
varies	O
in	O
B-cell	O
subsets	O
and	O
subtypes	O
of	O
B-cell	O
NHL	O
.	O
The	O
high	O
levels	O
of	O
BSAP	B-protein
,	O
especially	O
those	O
found	O
in	O
large-cell	O
lymphomas	O
and	O
in	O
some	O
follicular	O
lymphomas	O
,	O
may	O
be	O
a	O
consequence	O
of	O
deregulated	O
gene	O
expression	O
and	O
suggest	O
a	O
possible	O
involvement	O
of	O
PAX-5	B-protein
in	O
certain	O
B-cell	O
malignancies	O
.	O
This	O
is	O
a	O
US	O
government	O
work	O
.	O
There	O
are	O
no	O
restrictions	O
on	O
its	O
use	O
.	O
Mitogen	O
and	O
growth	O
factor-induced	O
activation	O
of	O
a	O
STAT-like	O
molecule	O
in	O
channel	O
catfish	O
lymphoid	O
cells	O
.	O
This	O
article	O
describes	O
the	O
identification	O
of	O
a	O
putative	B-protein
STAT	I-protein
molecule	I-protein
in	O
the	O
channel	O
catfish	O
(	O
Ictalurus	O
punctatus	O
)	O
,	O
the	O
first	O
report	O
of	O
such	O
a	O
molecule	O
in	O
a	O
'lower	O
'	O
vertebrate	O
.	O
A	O
monoclonal	B-protein
antibody	I-protein
against	O
human	B-protein
STAT6	I-protein
recognizes	O
an	O
approximately	O
100	O
kDa	O
molecule	O
that	O
becomes	O
activated	O
and	O
translocates	O
to	O
the	O
nucleus	O
upon	O
both	O
growth	O
factor	O
and	O
mitogen	O
stimulation	O
of	O
catfish	O
leukocytes	O
.	O
This	O
presumed	O
catfish	O
STAT	O
binds	O
the	O
mammalian	O
interferon-gamma	O
activation	O
site	O
,	O
a	O
known	O
motif	O
of	O
mammalian	O
STAT	O
binding	O
,	O
as	O
shown	O
by	O
electromobility	O
shift	O
assays	O
.	O
Purification	O
of	O
the	O
proteins	O
present	O
in	O
these	O
DNA	O
complexes	O
confirms	O
that	O
the	O
catfish	O
reactive	O
molecule	O
binds	O
to	O
the	O
interferon-gamma	O
activation	O
site	O
sequence	O
.	O
These	O
results	O
suggest	O
that	O
STAT	B-protein
molecules	I-protein
have	O
been	O
highly	O
conserved	O
in	O
vertebrate	O
evolution	O
.	O
Isolation	O
and	O
analysis	O
of	O
a	O
T	O
cell	O
clone	O
variant	O
exhibiting	O
constitutively	B-protein
phosphorylated	I-protein
Ser133	I-protein
cAMP	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
.	O
In	O
driving	O
T	O
cell	O
proliferation	O
,	O
IL-2	B-protein
stimulates	O
a	O
new	O
program	O
of	O
gene	O
expression	O
that	O
includes	O
proliferating	O
cell	O
nuclear	O
antigen	O
(	O
PCNA	O
)	O
,	O
a	O
requisite	O
processivity	O
factor	O
for	O
DNA	O
polymerase	O
delta	O
.	O
PCNA	O
transcription	O
is	O
regulated	O
in	O
part	O
through	O
tandem	O
CRE	O
sequences	O
in	O
the	O
promoter	O
and	O
CRE	B-protein
binding	I-protein
proteins	I-protein
;	O
IL-2	B-protein
stimulates	O
CREB	B-protein
phosphorylation	O
in	O
the	O
resting	O
cloned	O
T	O
lymphocyte	O
,	O
L2	O
.	O
After	O
culturing	O
L2	O
cells	O
for	O
greater	O
than	O
91	O
days	O
,	O
we	O
consistently	O
isolate	O
a	O
stable	O
variant	O
that	O
exhibits	O
constitutive	O
CREB	B-protein
phosphorylation	O
.	O
L2	O
and	O
L2	O
variant	O
cells	O
were	O
tested	O
for	O
IL-2	B-protein
responsiveness	O
and	O
rapamycin	O
sensitivity	O
with	O
respect	O
to	O
specific	O
kinase	O
activity	O
,	O
PCNA	O
expression	O
and	O
proliferation	O
.	O
In	O
L2	O
cells	O
,	O
IL-2	B-protein
stimulated	O
and	O
rapamycin	O
inhibited	O
the	O
following	O
:	O
cAMP-independent	O
CREB	B-protein
kinase	I-protein
activity	O
,	O
PCNA	O
expression	O
and	O
proliferation	O
.	O
In	O
L2	O
variant	O
cells	O
,	O
CREB	B-protein
kinase	I-protein
activity	O
was	O
constitutively	O
high	O
;	O
IL-2	B-protein
stimulated	O
and	O
rapamycin	O
blocked	O
PCNA	O
expression	O
and	O
proliferation	O
.	O
These	O
results	O
indicate	O
that	O
IL-2	B-protein
induces	O
a	O
rapamycin-sensitive	O
,	O
cAMP-independent	O
CREB	B-protein
kinase	I-protein
activity	O
in	O
L2	O
cells	O
.	O
However	O
,	O
phosphorylation	O
of	O
CREB	B-protein
alone	O
is	O
not	O
sufficient	O
to	O
drive	O
PCNA	O
expression	O
and	O
L2	O
cell	O
proliferation	O
in	O
the	O
absence	O
of	O
IL-2	B-protein
.	O
Serotonin	O
derivative	O
,	O
N-	O
(	O
p-coumaroyl	O
)	O
serotonin	O
,	O
inhibits	O
the	O
production	O
of	O
TNF-alpha	B-protein
,	O
IL-1alpha	B-protein
,	O
IL-1beta	B-protein
,	O
and	O
IL-6	B-protein
by	O
endotoxin-stimulated	O
human	O
blood	O
monocytes	O
.	O
We	O
have	O
reported	O
that	O
N-	O
(	O
p-coumaroyl	O
)	O
serotonin	O
(	O
CS	O
)	O
and	O
its	O
derivatives	O
with	O
antioxidative	O
activity	O
are	O
present	O
in	O
safflower	O
seeds	O
.	O
As	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
are	O
implicated	O
in	O
the	O
signaling	O
of	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
we	O
examined	O
whether	O
CS	O
has	O
a	O
suppressive	O
effect	O
on	O
inflammatory	O
cytokine	O
generation	O
from	O
human	O
monocyte	O
s	O
in	O
vitro	O
.	O
CS	O
at	O
50-200	O
microM	O
reduced	O
tumor	B-protein
necrosis	I-protein
factor	I-protein
(	I-protein
TNF	I-protein
)	I-protein
,	O
interleukin-1	O
(	O
IL-1	B-protein
)	O
,	O
and	O
IL-6	B-protein
activities	O
in	O
the	O
culture	O
supernatants	O
from	O
LPS-stimulated	O
human	O
blood	O
monocytes	O
without	O
cytotoxicity	O
.	O
ELISA	O
assay	O
revealed	O
that	O
the	O
production	O
of	O
TNF-alpha	B-protein
,	O
IL-1alpha	B-protein
,	O
IL-1beta	B-protein
,	O
and	O
IL-6	B-protein
was	O
inhibited	O
by	O
CS	O
.	O
Northern	O
blot	O
analysis	O
showed	O
that	O
LPS-induced	O
expression	O
of	O
these	O
cytokine	O
mRNA	O
in	O
monocytes	O
was	O
suppressed	O
by	O
CS	O
.	O
NF-kappaB	O
activation	O
was	O
also	O
inhibited	O
by	O
CS	O
.	O
These	O
findings	O
indicate	O
that	O
CS	O
has	O
a	O
suppressive	O
effect	O
on	O
proinflammatory	O
cytokine	O
production	O
from	O
monocytes	O
,	O
and	O
this	O
effect	O
is	O
based	O
in	O
part	O
on	O
the	O
suppression	O
of	O
cytokine	O
mRNA	O
expression	O
through	O
inhibition	O
of	O
NF-kappaB	B-protein
activation	O
.	O
Elevated	O
expression	O
of	O
differentiation	O
inhibitory	O
factor	O
nm23	O
mRNA	O
in	O
monoblastic	O
crisis	O
of	O
a	O
patient	O
with	O
chronic	O
myelogenous	O
leukemia	O
.	O
Differentiation	O
inhibitory	O
factor	O
nm23	O
gene	O
has	O
been	O
found	O
to	O
be	O
expressed	O
in	O
high	O
quantities	O
in	O
acute	O
myelogenous	O
leukemia	O
(	O
AML	O
)	O
,	O
especially	O
in	O
acute	O
monocytic	O
leukemia	O
(	O
AML-M5	O
)	O
and	O
is	O
suggested	O
as	O
a	O
new	O
prognostic	O
factor	O
in	O
AML-M5	O
.	O
We	O
report	O
an	O
example	O
of	O
elevated	O
expression	O
of	O
nm23	O
mRNA	O
in	O
a	O
patient	O
with	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
who	O
developed	O
monoblastic	O
crisis	O
.	O
Relative	O
levels	O
of	O
nm23-H1	O
and	O
-H2	O
mRNA	O
extracted	O
from	O
the	O
patient	O
's	O
peripheral	O
blood	O
mononuclear	O
cells	O
and	O
bone	O
marrow	O
mononuclear	O
cells	O
were	O
measured	O
by	O
quantitative	O
reverse	O
transcriptase	O
polymerase	O
chain	O
reaction	O
.	O
The	O
level	O
of	O
nm23-H1	O
mRNA	O
in	O
CML	O
cells	O
at	O
the	O
chronic	O
phase	O
was	O
as	O
high	O
as	O
that	O
in	O
bone	O
marrow	O
cells	O
from	O
healthy	O
volunteers	O
.	O
The	O
mRNA	O
level	O
of	O
nm23-H2	O
was	O
slightly	O
below	O
the	O
normal	O
level	O
.	O
At	O
blastic	O
crisis	O
,	O
however	O
,	O
expression	O
of	O
both	O
nm23-H1	O
and	O
-H2	O
mRNA	O
was	O
elevated	O
to	O
about	O
three	O
to	O
nine	O
times	O
of	O
that	O
at	O
the	O
chronic	O
phase	O
.	O
Proliferated	O
blastic	O
cells	O
were	O
positive	O
for	O
non-specific	O
esterase	O
,	O
and	O
the	O
serum	O
lysozyme	O
level	O
was	O
elevated	O
and	O
diagnosed	O
as	O
monoblastic	O
crisis	O
.	O
The	O
patient	O
received	O
combined	O
chemotherapy	O
but	O
response	O
was	O
partial	O
.	O
These	O
findings	O
are	O
compatible	O
with	O
our	O
previous	O
report	O
that	O
nm23	O
gene	O
is	O
overexpressed	O
in	O
monocytic	O
leukemia	O
.	O
Increased	O
transcription	O
decreases	O
the	O
spontaneous	O
mutation	O
rate	O
at	O
the	O
thymidine	O
kinase	O
locus	O
in	O
human	O
cells	O
.	O
Transcription	O
increases	O
DNA	O
repair	O
efficiency	O
and	O
modulates	O
the	O
distribution	O
of	O
certain	O
types	O
of	O
DNA	O
damage	O
.	O
Furthermore	O
,	O
increased	O
transcription	O
level	O
stimulates	O
spontaneous	O
mutation	O
rate	O
in	O
yeast	O
.	O
We	O
explored	O
whether	O
transcription	O
level	O
affects	O
spontaneous	O
mutation	O
rate	O
in	O
human	O
cells	O
.	O
We	O
first	O
developed	O
two	O
thymidine	O
kinase	O
(	O
tk	O
)	O
inducible	O
human	O
cell	O
lines	O
using	O
the	O
Gal4-Estrogen	O
receptor	O
system	O
.	O
In	O
our	O
TK6i-G3	O
and	O
G9	O
tk	O
heterozygous	O
cell	O
lines	O
,	O
the	O
active	O
tk	O
allele	O
is	O
linked	O
to	O
an	O
inducible	O
promoter	O
element	O
.	O
Tk	O
mRNA	O
is	O
induced	O
following	O
treatment	O
with	O
estrogen	O
.	O
Spontaneous	O
mutation	O
rate	O
was	O
significantly	O
decreased	O
in	O
human	O
cell	O
lines	O
after	O
induction	O
in	O
contrast	O
to	O
the	O
report	O
in	O
yeast	O
.	O
Thus	O
,	O
humans	O
may	O
have	O
evolved	O
different	O
or	O
additional	O
mechanisms	O
to	O
deal	O
with	O
transcription	O
related	O
spontaneous	O
mutagenesis	O
.	O
Copyright	O
1998	O
Elsevier	O
Science	O
B.V	O
.	O
All	O
rights	O
reserved	O
.	O
Mutation	O
of	O
BCL-6	O
gene	O
in	O
normal	O
B	O
cells	O
by	O
the	O
process	O
of	O
somatic	O
hypermutation	O
of	O
Ig	O
genes	O
.	O
Immunoglobulin	O
(	O
Ig	O
)	O
genes	O
are	O
hypermutated	O
in	O
B	O
lymphocytes	O
that	O
are	O
the	O
precursors	O
to	O
memory	O
B	O
cells	O
.	O
The	O
mutations	O
are	O
linked	O
to	O
transcription	O
initiation	O
,	O
but	O
non-Ig	O
promoters	O
are	O
permissible	O
for	O
the	O
mutation	O
process	O
;	O
thus	O
,	O
other	O
genes	O
expressed	O
in	O
mutating	O
B	O
cells	O
may	O
also	O
be	O
subject	O
to	O
somatic	O
hypermutation	O
.	O
Significant	O
mutations	O
were	O
not	O
observed	O
in	O
c-MYC	O
,	O
S14	O
,	O
or	O
alpha-fetoprotein	O
(	O
AFP	O
)	O
genes	O
,	O
but	O
BCL-6	O
was	O
highly	O
mutated	O
in	O
a	O
large	O
proportion	O
of	O
memory	O
B	O
cells	O
of	O
normal	O
individuals	O
.	O
The	O
mutation	O
pattern	O
was	O
similar	O
to	O
that	O
of	O
Ig	O
genes	O
.	O
CD28-mediated	O
activation	O
in	O
CD45RA+	O
and	O
CD45RO+	O
T	O
cells	O
:	O
enhanced	O
levels	O
of	O
reactive	O
oxygen	O
intermediates	O
and	O
c-Rel	B-protein
nuclear	O
translocation	O
in	O
CD45RA+	O
cells	O
.	O
We	O
have	O
analyzed	O
the	O
effect	O
of	O
complete	O
T	O
cell	O
activation	O
(	O
anti-CD3	B-protein
plus	O
anti-CD28	B-protein
)	O
on	O
the	O
activation	O
of	O
NF-kappaB	B-protein
in	O
CD45RA+	O
(	O
naive	O
)	O
and	O
CD45RO+	O
(	O
memory/effector	O
)	O
T	O
cells	O
.	O
Long	O
exposure	O
(	O
24	O
h	O
)	O
induced	O
stronger	O
NF-kappaB	B-protein
DNA	O
binding	O
in	O
CD45RA+	O
cells	O
than	O
in	O
CD45RO+	O
cells	O
.	O
Analysis	O
of	O
the	O
nuclear	B-protein
c-Rel	I-protein
protein	I-protein
indicated	O
that	O
after	O
anti-CD3+anti-CD28	O
stimulation	O
the	O
level	O
of	O
c-Rel	B-protein
was	O
higher	O
in	O
CD45RA+	O
cells	O
.	O
Analysis	O
of	O
the	O
cytoplasmic	O
inhibitor	O
IkappaBalpha	B-protein
indicated	O
that	O
anti-CD3+anti-CD28	O
stimulation	O
induced	O
a	O
long-lasting	O
degradation	O
in	O
CD45RA+	O
cells	O
but	O
in	O
CD45RO+	O
cells	O
the	O
degradation	O
process	O
was	O
more	O
rapid	O
.	O
Because	O
the	O
CD28	O
costimulus	O
is	O
known	O
to	O
induce	O
the	O
production	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
,	O
the	O
intracellular	O
ROI	O
levels	O
in	O
CD45RA+	O
and	O
CD45RO+	O
cells	O
were	O
compared	O
by	O
flow	O
cytometry	O
.	O
ROIs	O
were	O
produced	O
in	O
both	O
cell	O
types	O
,	O
but	O
more	O
strongly	O
in	O
CD45RA+	O
cells	O
.	O
The	O
data	O
presented	O
in	O
this	O
study	O
further	O
emphasize	O
the	O
differences	O
between	O
CD45RA+	O
and	O
CD45RO+	O
T	O
lymphocytes	O
in	O
ROI-dependent	O
signaling	O
pathways	O
.	O
Non-Hodgkin	O
's	O
lymphoma	O
involving	O
bilateral	O
breasts	O
[	O
see	O
comments	O
]	O
We	O
describe	O
here	O
two	O
cases	O
of	O
diffuse	O
large	O
cell	O
type	O
non-Hodgkin	O
's	O
lymphoma	O
affecting	O
the	O
bilateral	O
breasts	O
.	O
The	O
contralateral	O
tumor	O
in	O
one	O
case	O
appeared	O
17	O
months	O
after	O
the	O
first	O
mastectomy	O
,	O
whereas	O
the	O
bilateral	O
tumors	O
occurred	O
concurrently	O
in	O
the	O
other	O
patient	O
who	O
was	O
pregnant	O
and	O
showed	O
widespread	O
dissemination	O
at	O
initial	O
presentation	O
.	O
Lymphoma	O
cells	O
from	O
both	O
cases	O
showed	O
the	O
mature	O
B-cell	O
immunophenotype	O
and	O
had	O
rearrangements	O
of	O
the	O
BCL6	O
gene	O
.	O
Both	O
patients	O
developed	O
progressive	O
disease	O
despite	O
chemo-radiotherapy	O
and	O
died	O
of	O
leukemic	O
manifestations	O
.	O
There	O
were	O
no	O
apparent	O
pathological	O
features	O
of	O
lymphomas	O
of	O
mucosa-associated	O
lymphoid	O
tissue	O
origin	O
Biochemical	O
characterization	O
of	O
MIP-1	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
.	O
A	O
family	O
of	O
hematopoietic	B-protein
specific	I-protein
transcription	I-protein
factors	I-protein
,	O
MIP-1	B-protein
alpha	I-protein
nuclear	I-protein
protein	I-protein
(	O
MNP	O
)	O
family	O
,	O
has	O
recently	O
been	O
identified	O
.	O
They	O
are	O
intimately	O
involved	O
in	O
regulating	O
the	O
transcription	O
of	O
the	O
huMIP-1	O
alpha	O
gene	O
in	O
monocytes	O
,	O
T-cells	O
,	O
and	O
transformed	O
B-cells	O
.	O
One	O
member	O
of	O
the	O
family	O
(	O
MNP-1	O
)	O
is	O
essential	O
for	O
promoter	O
activity	O
in	O
monocytes	O
and	O
B-cells	O
,	O
while	O
another	O
(	O
MNP-2	O
)	O
is	O
required	O
for	O
full	O
promotor	O
activity	O
in	O
T-cells	O
.	O
A	O
third	O
member	O
of	O
the	O
family	O
(	O
MNP-3	O
)	O
is	O
expressed	O
in	O
PMA	O
induced	O
HL60	O
cells	O
and	O
probably	O
has	O
a	O
role	O
in	O
monocyte	O
differentiation	O
.	O
In	O
this	O
communication	O
we	O
demonstrate	O
by	O
two	O
techniques	O
that	O
MNP-1	O
and	O
MNP-2	B-protein
are	O
distinct	O
but	O
related	O
factors	O
,	O
and	O
we	O
present	O
further	O
evidence	O
to	O
show	O
that	O
MNP-1	O
acts	O
as	O
a	O
heterodimer	O
.	O
Bcl-3	O
expression	O
and	O
nuclear	O
translocation	O
are	O
induced	O
by	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
and	O
erythropoietin	O
in	O
proliferating	O
human	O
erythroid	O
precursors	O
.	O
Bcl-3	O
is	O
a	O
proto-oncogene	O
involved	O
in	O
the	O
chromosomal	O
translocation	O
t	O
(	O
14	O
;	O
19	O
)	O
found	O
in	O
some	O
patients	O
with	O
chronic	O
lymphocytic	O
leukemia	O
.	O
It	O
shares	O
structural	O
similarities	O
with	O
and	O
is	O
a	O
member	O
of	O
the	O
IkappaB	B-protein
family	I-protein
of	I-protein
proteins	I-protein
.	O
In	O
this	O
report	O
,	O
involvement	O
of	O
Bcl-3	O
in	O
hematopoietic	O
growth	O
factor-stimulated	O
erythroid	O
proliferation	O
and	O
differentiation	O
was	O
examined	O
.	O
In	O
TF-1	O
cells	O
,	O
an	O
erythroleukemia	O
cell	O
line	O
,	O
granulocyte-macrophage	B-protein
colony-stimulating	I-protein
factor	I-protein
(	O
GM-CSF	B-protein
)	O
and	O
erythropoietin	O
(	O
Epo	O
)	O
greatly	O
enhanced	O
Bcl-3	O
expression	O
at	O
both	O
the	O
protein	O
and	O
mRNA	O
levels	O
in	O
association	O
with	O
stimulation	O
of	O
proliferation	O
.	O
Bcl-3	B-protein
protein	I-protein
was	O
also	O
highly	O
expressed	O
in	O
early	O
burst-forming	O
unit-erythroid	O
(	O
BFU-E	O
)	O
-derived	O
erythroid	O
precursors	O
(	O
day	O
7	O
)	O
and	O
decreased	O
during	O
maturation	O
(	O
days	O
10	O
and	O
14	O
)	O
,	O
suggesting	O
that	O
Bcl-3	O
is	O
involved	O
in	O
normal	O
erythroid	O
proliferation	O
.	O
In	O
these	O
hematopoietic	O
cells	O
,	O
Bcl-3	O
was	O
hyperphosphorylated	O
.	O
GM-CSF	B-protein
and	O
Epo	O
modulated	O
the	O
subcellular	O
localization	O
of	O
Bcl-3	O
.	O
Upon	O
stimulation	O
of	O
TF-1	O
cells	O
with	O
GM-CSF	B-protein
or	O
Epo	O
,	O
the	O
nuclear	O
translocation	O
of	O
Bcl-3	O
was	O
dramatically	O
enhanced	O
.	O
Overexpression	O
of	O
Bcl-3	O
in	O
TF-1	O
cells	O
by	O
transient	O
transfection	O
along	O
with	O
the	O
NF-kappaB	B-protein
factors	I-protein
p50	B-protein
or	O
p52	O
resulted	O
in	O
significant	O
induction	O
of	O
an	O
human	O
immunodeficiency	O
virus-type	O
1	O
(	O
HIV-1	O
)	O
kappaB-TATA-luceriferase	O
reporter	O
plasmid	O
,	O
demonstrating	O
that	O
Bcl-3	O
has	O
a	O
positive	O
role	O
in	O
transactivation	O
of	O
kappaB-containing	O
genes	O
in	O
erythroid	O
cells	O
.	O
Stimulation	O
with	O
GM-CSF	B-protein
enhanced	O
c-myb	O
mRNA	O
expression	O
in	O
these	O
cells	O
.	O
Bcl-3	O
in	O
nuclear	O
extracts	O
of	O
TF-1	O
cells	O
bound	O
to	O
a	O
kappaB	O
enhancer	O
in	O
the	O
c-myb	O
promoter	O
together	O
with	O
NF-kappaB2/p52	O
and	O
this	O
binding	O
activity	O
was	O
enhanced	O
by	O
GM-CSF	B-protein
stimulation	O
.	O
Furthermore	O
,	O
cotransfection	O
of	O
Bcl-3	O
with	O
p52	O
or	O
p50	B-protein
in	O
TF-1	O
cells	O
resulted	O
in	O
significant	O
activation	O
of	O
a	O
c-myb	O
kappaB-TATA-luceriferase	O
reporter	O
plasmid	O
.	O
These	O
findings	O
suggest	O
that	O
Bcl-3	O
may	O
participate	O
in	O
the	O
transcriptional	O
regulation	O
of	O
certain	O
kappaB-containing	O
genes	O
involved	O
in	O
hematopoiesis	O
,	O
including	O
c-myb	O
.	O
Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O
5-Lipoxygenase	O
compartmentalization	O
in	O
granulocytic	O
cells	O
is	O
modulated	O
by	O
an	O
internal	O
bipartite	O
nuclear	O
localizing	O
sequence	O
and	O
nuclear	B-protein
factor	I-protein
kappa	I-protein
B	I-protein
complex	I-protein
formation	O
.	O
A	O
region	O
of	O
basic	B-protein
amino	I-protein
acids	I-protein
spanning	O
residues	O
639-656	O
in	O
the	O
human	O
5-lipoxygenase	O
sequence	O
resembles	O
a	O
consensus	O
bipartite	O
nuclear	O
localizing	O
sequence	O
.	O
A	O
synthetic	O
peptide	O
consisting	O
of	O
the	O
Kaposi	O
fibroblast	O
growth	O
factor	O
signal	O
sequence	O
fused	O
to	O
the	O
5-lipoxygenase639-656	O
bipartite	O
nuclear	O
localizing	O
sequence	O
has	O
a	O
prominent	O
inhibitory	O
effect	O
on	O
5-lipoxygenase	O
catalysis	O
in	O
granulocytic	O
HL-60	O
cells	O
activated	O
by	O
calcium	O
ionophor	O
A23187	O
.	O
Recombinant	O
5-lipoxygenase	O
was	O
not	O
affected	O
by	O
the	O
peptide	O
.	O
The	O
peptide	O
also	O
inhibited	O
redistribution	O
of	O
5-lipoxygenase	O
from	O
the	O
cytosol	O
to	O
the	O
nuclear	O
membrane	O
of	O
HL-60	O
cells	O
stimulated	O
by	O
A23187	O
.	O
5-Lipoxygenase	B-protein
protein	I-protein
was	O
detected	O
in	O
nuclear	O
factor	O
kappaB	O
(	O
NF-kappaB	B-protein
)	O
p65	B-protein
subunit	I-protein
immunoprecipitate	O
fractions	O
prepared	O
from	O
HL-60	O
cell	O
lysates	O
.	O
The	O
amount	O
of	O
5-lipoxygenase	B-protein
protein	I-protein
coimmunoprecipitated	O
by	O
NF-kappaB	B-protein
antiserum	O
was	O
increased	O
following	O
A23187	O
stimulation	O
.	O
In	O
cells	O
treated	O
with	O
agents	O
that	O
block	O
5-lipoxygenase	O
translocation	O
to	O
the	O
nucleus	O
,	O
5-lipoxygenase	O
protein	O
appearing	O
in	O
the	O
NF-kappaB	B-protein
immunoprecipitate	O
was	O
diminished	O
.	O
Our	O
results	O
implicate	O
an	O
internal	O
bipartite	O
nuclear	O
localizing	O
sequence	O
as	O
a	O
regulatory	O
domain	O
that	O
modulates	O
5-lipoxygenase	O
redistribution	O
and	O
catalysis	O
in	O
granulocytic	O
cells	O
.	O
Additionally	O
,	O
our	O
results	O
suggest	O
that	O
molecular	O
determinants	O
which	O
govern	O
5-lipoxygenase	O
and	O
NF-kappaB	O
redistribution	O
to	O
the	O
nucleus	O
may	O
be	O
coordinately	O
controlled	O
in	O
granulocytic	O
cells	O
.	O
Copyright	O
1998	O
Academic	O
Press	O
.	O
Inhibition	O
of	O
CD28/CD3-mediated	O
costimulation	O
of	O
naive	O
and	O
memory	O
human	O
T	O
lymphocytes	O
by	O
intracellular	O
incorporation	O
of	O
polyclonal	B-protein
antibodies	I-protein
specific	O
for	O
the	O
activator	B-protein
protein-1	I-protein
transcriptional	I-protein
complex	I-protein
.	O
A	O
number	O
of	O
indirect	O
methods	O
have	O
been	O
utilized	O
in	O
demonstrating	O
activator	B-protein
protein-1	I-protein
transcription	I-protein
factor	I-protein
function	O
in	O
IL-2	O
promoter	O
activity	O
.	O
However	O
,	O
there	O
has	O
been	O
no	O
direct	O
demonstration	O
that	O
activator	B-protein
protein-1	I-protein
is	O
involved	O
in	O
CD28-dependent	O
costimulation	O
of	O
IL-2	O
gene	O
transcription	O
in	O
freshly	O
isolated	O
naive	O
and	O
memory	O
human	O
T	O
lymphocytes	O
.	O
To	O
address	O
this	O
issue	O
,	O
the	O
method	O
of	O
scrape	O
loading	O
was	O
applied	O
to	O
purified	O
peripheral	O
blood	O
T	O
lymphocytes	O
.	O
Since	O
scrape	O
loading	O
relies	O
on	O
adherent	O
cells	O
,	O
peripheral	O
blood	O
human	O
T	O
(	O
PB-T	O
)	O
cells	O
were	O
immobilized	O
on	O
the	O
nonspecific	O
cell	O
attachment	O
factor	O
poly-L-lysine	O
.	O
Cells	O
scraped	O
off	O
poly-L-lysine	O
in	O
the	O
presence	O
of	O
Ig	B-protein
FITC	I-protein
efficiently	O
incorporated	O
Ig	O
,	O
with	O
relatively	O
uniform	O
fluorescence	O
.	O
T	O
cells	O
retained	O
their	O
physical	O
parameters	O
as	O
measured	O
by	O
forward	O
and	O
side	O
light	O
scatter	O
,	O
and	O
functional	O
activity	O
as	O
measured	O
by	O
costimulation	O
of	O
proliferation	O
and	O
IL-2	B-protein
production	O
after	O
being	O
scraped	O
off	O
this	O
substrate	O
.	O
CD28/CD3-costimulated	O
T	O
cells	O
produced	O
intracellular	O
IL-2	B-protein
from	O
all	O
subsets	O
measured	O
(	O
CD4+	O
,	O
CD4-	O
,	O
CD45RO+	O
,	O
and	O
CD45RO-	O
)	O
.	O
IL-2	O
production	O
and	O
intracellular	O
accumulation	O
in	O
nonscraped	O
PB-T	O
cells	O
activated	O
with	O
CD28/CD3	O
coligation	O
were	O
skewed	O
favoring	O
CD45RO+	O
and	O
CD4+	O
subsets	O
,	O
as	O
was	O
IL-2	O
production	O
in	O
scraped	O
PB-T	O
cells	O
.	O
The	O
intracellular	O
incorporation	O
of	O
Abs	B-protein
specific	O
for	O
c-Fos	B-protein
and	O
c-Jun	B-protein
family	I-protein
members	I-protein
by	O
scrape	O
loading	O
inhibited	O
the	O
production	O
and	O
intracellular	O
accumulation	O
of	O
IL-2	B-protein
within	O
6	O
h	O
of	O
costimulation	O
with	O
PMA/ionomycin	O
,	O
or	O
costimulation	O
by	O
CD28	B-protein
and	O
CD3	O
ligation	O
.	O
Scrape	O
loading	O
thus	O
provides	O
an	O
efficient	O
mechanism	O
for	O
intracellular	O
incorporation	O
of	O
macromolecules	O
,	O
and	O
the	O
first	O
direct	O
evidence	O
that	O
c-Fos	B-protein
and	O
c-Jun	B-protein
are	O
involved	O
in	O
transcription	O
of	O
the	O
IL-2	O
gene	O
within	O
its	O
correct	O
chromosomal	O
context	O
,	O
in	O
resting	O
human	O
T	O
lymphocyte	O
subpopulations	O
.	O
Differential	O
expression	O
of	O
Nur77	B-protein
family	I-protein
members	I-protein
in	O
human	O
T-lymphotropic	O
virus	O
type	O
1-infected	O
cells	O
:	O
transactivation	O
of	O
the	O
TR3/nur77	O
gene	O
by	O
Tax	B-protein
protein	I-protein
.	O
We	O
analyzed	O
the	O
differential	O
expression	O
and	O
regulation	O
of	O
three	O
members	O
of	O
the	O
Nur77	B-protein
transcription	I-protein
factor	I-protein
family	I-protein
by	O
the	O
human	O
T-lymphotropic	O
virus	O
type	O
1	O
(	O
HTLV-1	O
)	O
Tax	B-protein
protein	I-protein
.	O
We	O
have	O
demonstrated	O
that	O
in	O
both	O
HTLV-1-infected	O
cells	O
and	O
Tax-expressing	O
JPX-9	O
cells	O
,	O
TR3/nur77	O
is	O
highly	O
expressed	O
,	O
whereas	O
neither	O
NOR-1	O
nor	O
NOT	O
expression	O
is	O
detectable	O
.	O
Transient	O
transfection	O
analysis	O
further	O
confirmed	O
the	O
Tax	O
transactivation	O
of	O
the	O
TR3/nur77	O
promoter	O
but	O
not	O
the	O
NOR-1	O
promoter	O
in	O
different	O
cell	O
types	O
.	O
Furthermore	O
,	O
expression	O
of	O
a	O
luciferase	O
reporter	O
gene	O
driven	O
by	O
the	O
NGFI-B	O
(	O
rat	O
homolog	O
of	O
TR3/Nur77	O
)	O
response	O
element	O
(	O
NBRE	O
)	O
provided	O
evidence	O
that	O
Tax	B-protein
-mediated	O
transactivation	O
resulted	O
in	O
the	O
induction	O
of	O
a	O
functional	B-protein
protein	I-protein
.	O
Cotransfection	O
assays	O
with	O
the	O
TR3/nur77	O
promoter	O
sequence	O
or	O
the	O
NBRE	O
binding	O
motif	O
together	O
with	O
a	O
series	O
of	O
Tax	B-protein
mutants	I-protein
have	O
shown	O
that	O
Tax	B-protein
-induced	O
TR3/nur77	O
expression	O
is	O
mediated	O
by	O
CREB/ATF-related	B-protein
transcription	I-protein
factors	I-protein
.	O
Negative	O
regulation	O
of	O
the	O
heat	O
shock	O
transcriptional	O
response	O
by	O
HSBP1	O
.	O
In	O
response	O
to	O
stress	O
,	O
heat	B-protein
shock	I-protein
factor	I-protein
1	I-protein
(	O
HSF1	O
)	O
acquires	O
rapid	O
DNA	O
binding	O
and	O
transient	O
transcriptional	O
activity	O
while	O
undergoing	O
conformational	O
transition	O
from	O
an	O
inert	O
non-DNA-binding	O
monomer	O
to	O
active	B-protein
functional	I-protein
trimers	I-protein
.	O
Attenuation	O
of	O
the	O
inducible	O
transcriptional	O
response	O
occurs	O
during	O
heat	O
shock	O
or	O
upon	O
recovery	O
at	O
non-stress	O
conditions	O
and	O
involves	O
dissociation	O
of	O
the	O
HSF1	O
trimer	O
and	O
loss	O
of	O
activity	O
.	O
We	O
have	O
used	O
the	O
hydrophobic	O
repeats	O
of	O
the	O
HSF1	B-protein
trimerization	I-protein
domain	I-protein
in	O
the	O
yeast	O
two-hybrid	O
protein	O
interaction	O
assay	O
to	O
identify	O
heat	B-protein
shock	I-protein
factor	I-protein
binding	I-protein
protein	I-protein
1	I-protein
(	O
HSBP1	O
)	O
,	O
a	O
novel	O
,	O
conserved	O
,	O
76-amino-acid	B-protein
protein	I-protein
that	O
contains	O
two	O
extended	O
arrays	O
of	O
hydrophobic	O
repeats	O
that	O
interact	O
with	O
the	O
HSF1	O
heptad	O
repeats	O
.	O
HSBP1	B-protein
is	O
nuclear-localized	O
and	O
interacts	O
in	O
vivo	O
with	O
the	O
active	O
trimeric	O
state	O
of	O
HSF1	B-protein
that	O
appears	O
during	O
heat	O
shock	O
.	O
During	O
attenuation	O
of	O
HSF1	O
to	O
the	O
inert	O
monomer	O
,	O
HSBP1	B-protein
associates	O
with	O
Hsp70	B-protein
.	O
HSBP1	O
negatively	O
affects	O
HSF1	O
DNA-binding	O
activity	O
,	O
and	O
overexpression	O
of	O
HSBP1	O
in	O
mammalian	O
cells	O
represses	O
the	O
transactivation	O
activity	O
of	O
HSF1	O
.	O
To	O
establish	O
a	O
biological	O
role	O
for	O
HSBP1	O
,	O
the	O
homologous	O
Caenorhabditis	O
elegans	O
protein	O
was	O
overexpressed	O
in	O
body	O
wall	O
muscle	O
cells	O
and	O
was	O
shown	O
to	O
block	O
activation	O
of	O
the	O
heat	O
shock	O
response	O
from	O
a	O
heat	O
shock	O
promoter-reporter	O
construct	O
.	O
Alteration	O
in	O
the	O
level	O
of	O
HSBP1	O
expression	O
in	O
C.	O
elegans	O
has	O
severe	O
effects	O
on	O
survival	O
of	O
the	O
animals	O
after	O
thermal	O
and	O
chemical	O
stress	O
,	O
consistent	O
with	O
a	O
role	O
for	O
HSBP1	B-protein
as	O
a	O
negative	O
regulator	O
of	O
the	O
heat	O
shock	O
response	O
.	O
Long-range	O
transcriptional	O
regulation	O
of	O
cytokine	O
gene	O
expression	O
.	O
Most	O
studies	O
on	O
the	O
control	O
of	O
cytokine	O
gene	O
expression	O
have	O
involved	O
the	O
functional	O
analysis	O
of	O
proximal	O
promoters	O
.	O
Recent	O
work	O
has	O
identified	O
distal	O
elements	O
that	O
mediate	O
long-range	O
cytokine	O
gene	O
regulation	O
and	O
has	O
implicated	O
chromatin	O
reorganization	O
in	O
regulation	O
of	O
cytokine	O
gene	O
loci	O
.	O
These	O
studies	O
have	O
begun	O
to	O
elucidate	O
the	O
basis	O
for	O
cell-specificity	O
and	O
high-level	O
expression	O
of	O
cytokine	O
genes	O
.	O
A	O
signaling	B-protein
complex	I-protein
of	O
Ca2+-calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
IV	I-protein
and	I-protein
protein	I-protein
phosphatase	I-protein
2A	I-protein
[	O
see	O
comments	O
]	O
Stimulation	O
of	O
T	O
lymphocytes	O
results	O
in	O
a	O
rapid	O
increase	O
in	O
intracellular	O
calcium	O
concentration	O
(	O
[	O
Ca2+	O
]	O
i	O
)	O
that	O
parallels	O
the	O
activation	O
of	O
Ca2+-calmodulin-dependent	B-protein
protein	I-protein
kinase	I-protein
IV	I-protein
(	I-protein
CaMKIV	I-protein
)	O
,	O
a	O
nuclear	B-protein
enzyme	I-protein
that	O
can	O
phosphorylate	O
and	O
activate	O
the	O
cyclic	O
adenosine	O
monophosphate	O
(	O
cAMP	B-protein
)	I-protein
response	I-protein
element-binding	I-protein
protein	I-protein
(	O
CREB	B-protein
)	O
.	O
However	O
,	O
inactivation	O
of	O
CaMKIV	B-protein
occurs	O
despite	O
the	O
sustained	O
increase	O
in	O
[	O
Ca2+	O
]	O
i	O
that	O
is	O
required	O
for	O
T	O
cell	O
activation	O
.	O
A	O
stable	O
and	O
stoichiometric	B-protein
complex	I-protein
of	O
CaMKIV	B-protein
with	O
protein	B-protein
serine-threonine	I-protein
phosphatase	I-protein
2A	I-protein
(	O
PP2A	O
)	O
was	O
identified	O
in	O
which	O
PP2A	O
dephosphorylates	O
CaMKIV	B-protein
and	O
functions	O
as	O
a	O
negative	B-protein
regulator	I-protein
of	I-protein
CaMKIV	I-protein
signaling	O
.	O
In	O
Jurkat	O
T	O
cells	O
,	O
inhibition	O
of	O
PP2A	O
activity	O
by	O
small	O
t	O
antigen	O
enhanced	O
activation	O
of	O
CREB	B-protein
-mediated	O
transcription	O
by	O
CaMKIV	B-protein
.	O
These	O
findings	O
reveal	O
an	O
intracellular	O
signaling	O
mechanism	O
whereby	O
a	O
protein	O
serine-threonine	O
kinase	O
(	O
CaMKIV	O
)	O
is	O
regulated	O
by	O
a	O
tightly	B-protein
associated	I-protein
protein	I-protein
serine-threonine	I-protein
phosphatase	I-protein
(	O
PP2A	O
)	O
.	O
Hypoxia	O
down-regulates	O
MCP-1	O
expression	O
:	O
implications	O
for	O
macrophage	O
distribution	O
in	O
tumors	O
.	O
Monocyte	B-protein
chemoattractant	I-protein
protein	I-protein
1	I-protein
(	I-protein
MCP-1	I-protein
)	O
is	O
likely	O
to	O
contribute	O
to	O
the	O
macrophage	O
infiltrate	O
in	O
human	O
ovarian	O
carcinomas	O
.	O
Although	O
MCP-1	B-protein
is	O
predominantly	O
expressed	O
by	O
the	O
tumor	O
parenchyma	O
,	O
macrophages	O
accumulate	O
at	O
highest	O
density	O
in	O
necrotic	O
regions	O
,	O
which	O
are	O
associated	O
with	O
low	O
oxygen	O
tensions	O
.	O
Tumor	B-protein
necrosis	I-protein
factor	I-protein
alpha	I-protein
(	O
TNF-alpha	B-protein
)	O
can	O
stimulate	O
MCP-1	B-protein
production	O
and	O
is	O
also	O
present	O
within	O
ovarian	O
carcinomas	O
.	O
We	O
have	O
investigated	O
the	O
effect	O
of	O
hypoxia	O
both	O
on	O
MCP-1	B-protein
expression	O
in	O
ovarian	O
cancer	O
cell	O
lines	O
and	O
monocyte	O
migration	O
.	O
Hypoxia	O
down-regulated	O
TNF-alpha-induced	O
MCP-1	O
mRNA	O
and	O
protein	O
production	O
by	O
ovarian	O
cancer	O
cells	O
.	O
The	O
effect	O
was	O
mimicked	O
by	O
cobalt	O
chloride	O
and	O
desferrioxamine	O
,	O
consistent	O
with	O
a	O
specific	O
oxygen-sensing	O
mechanism	O
.	O
Unlike	O
antioxidants	O
,	O
hypoxia	O
did	O
not	O
inhibit	O
nuclear	B-protein
factor	I-protein
KB	I-protein
mobilization	O
.	O
Monocyte	O
migration	O
in	O
response	O
to	O
MCP-1	B-protein
was	O
also	O
diminished	O
under	O
hypoxic	O
conditions	O
.	O
Down-regulation	O
of	O
MCP-1	B-protein
expression	O
and	O
the	O
inhibition	O
of	O
monocyte	O
migration	O
are	O
independent	O
effects	O
of	O
hypoxia	O
that	O
may	O
contribute	O
to	O
the	O
distribution	O
of	O
macrophages	O
within	O
ovarian	O
tumors	O
.	O
Activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
inflammatory	O
bowel	O
disease	O
[	O
see	O
comments	O
]	O
BACKGROUND	O
:	O
Expression	O
of	O
pro-inflammatory	B-protein
cytokines	I-protein
is	O
increased	O
in	O
the	O
intestinal	O
lamina	O
propria	O
of	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O
Nuclear	O
factor	O
kappa	O
B	O
(	O
NF	B-protein
kappa	I-protein
B	I-protein
)	O
controls	O
transcription	O
of	O
inflammation	O
genes	O
.	O
On	O
activation	O
,	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
rapidly	O
released	O
from	O
its	O
cytoplasmic	O
inhibitor	O
(	O
I	B-protein
kappa	I-protein
B	I-protein
)	O
,	O
transmigrates	O
into	O
the	O
nucleus	O
,	O
and	O
binds	O
to	O
DNA	O
response	O
elements	O
in	O
gene	O
promoter	O
regions	O
.	O
AIMS	O
:	O
To	O
investigate	O
whether	O
increased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
is	O
important	O
in	O
IBD	O
and	O
may	O
be	O
down-regulated	O
by	O
anti-inflammatory	O
treatment	O
.	O
METHODS	O
:	O
Activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
was	O
determined	O
by	O
western	O
blot	O
assessment	O
and	O
electrophoretic	O
mobility	O
shift	O
assay	O
in	O
nuclear	O
extracts	O
of	O
colonic	O
biopsy	O
samples	O
as	O
well	O
as	O
lamina	O
propria	O
mononuclear	O
cells	O
.	O
RESULTS	O
:	O
Nuclear	O
levels	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
p65	I-protein
are	O
increased	O
in	O
lamina	O
propria	O
biopsy	O
specimens	O
from	O
patients	O
with	O
Crohn	O
's	O
disease	O
in	O
comparison	O
with	O
patients	O
with	O
ulcerative	O
colitis	O
and	O
controls	O
.	O
Increased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
was	O
detected	O
in	O
lamina	O
propria	O
mononuclear	O
cells	O
from	O
patients	O
with	O
active	B-protein
IBD	I-protein
.	O
Corticosteroids	O
strongly	O
inhibit	O
intestinal	O
NF	O
kappa	O
B	O
activation	O
in	O
IBD	O
in	O
vivo	O
and	O
in	O
vitro	O
by	O
stabilising	O
the	O
cytosolic	O
inhibitor	O
I	O
kappa	O
B	O
alpha	O
against	O
activation	O
induced	O
degradation	O
.	O
CONCLUSIONS	O
:	O
In	O
both	O
IBDs	O
,	O
but	O
particularly	O
Crohn	O
's	O
disease	O
,	O
increased	O
activation	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
inflammatory	O
response	O
.	O
Inhibition	O
of	O
NF	B-protein
kappa	I-protein
B	I-protein
activation	O
may	O
represent	O
a	O
mechanism	O
by	O
which	O
steroids	O
exert	O
an	O
anti-inflammatory	O
effect	O
in	O
IBD	O
Insufficient	O
glycemic	O
control	O
increases	O
nuclear	O
factor-kappa	O
B	O
binding	O
activity	O
in	O
peripheral	O
blood	O
mononuclear	O
cells	O
isolated	O
from	O
patients	O
with	O
type	O
1	O
diabetes	O
.	O
OBJECTIVE	O
:	O
The	O
redox-sensitive	B-protein
transcription	I-protein
factor	I-protein
nuclear	B-protein
factor-kappa	I-protein
B	I-protein
(	O
NF-kappa	B-protein
B	I-protein
)	O
is	O
believed	O
to	O
contribute	O
to	O
late	O
diabetic	O
complications	O
.	O
It	O
is	O
unknown	O
whether	O
NF-kappa	B-protein
B	I-protein
is	O
influenced	O
by	O
glycemic	O
control	O
.	O
RESEARCH	O
DESIGN	O
AND	O
METHODS	O
:	O
To	O
determine	O
whether	O
NF-kappa	B-protein
B	I-protein
is	O
activated	O
in	O
patients	O
with	O
insufficient	O
glycemic	O
control	O
(	O
HbA1c	O
>	O
10	O
%	O
)	O
,	O
we	O
developed	O
a	O
tissue	O
culture-independent	O
electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
-based	O
semiquantitative	O
detection	O
system	O
that	O
allowed	O
us	O
to	O
determine	O
NF-kappa	O
B	O
activation	O
in	O
ex	O
vivo-isolated	O
peripheral	O
blood	O
mononuclear	O
cells	O
(	O
PBMCs	O
)	O
.	O
We	O
included	O
43	O
patients	O
with	O
type	O
1	O
diabetes	O
in	O
this	O
cross-sectional	O
study	O
.	O
10	O
of	O
those	O
received	O
the	O
antioxidant	O
thioctic	O
acid	O
(	O
600	O
mg/day	O
)	O
for	O
2	O
weeks	O
.	O
RESULTS	O
:	O
Monocytes	O
of	O
patients	O
with	O
HbA1c	O
levels	O
>	O
10	O
%	O
demonstrated	O
significantly	O
higher	O
NF-kappa	O
B	O
binding	O
activity	O
in	O
an	O
EMSA	O
and	O
a	O
stronger	O
NF-kappa	O
B	O
staining	O
in	O
immunohistochemistry	O
than	O
monocytes	O
of	O
patients	O
with	O
HbA1c	O
levels	O
of	O
6-8	O
%	O
.	O
The	O
increase	O
in	O
NF-kappa	O
B	O
activation	O
correlated	O
with	O
an	O
increase	O
in	O
plasmatic	O
markers	O
of	O
lipid	O
peroxidation	O
.	O
Treatment	O
with	O
the	O
antioxidant	O
thioctic	O
acid	O
decreased	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
.	O
CONCLUSIONS	O
:	O
Hyperglycemia	O
induces	O
activation	O
of	O
the	O
transcription	B-protein
factor	I-protein
NF-kappa	I-protein
B	I-protein
in	O
ex	O
vivo-isolated	O
PBMCs	O
of	O
patients	O
with	O
type	O
1	O
diabetes	O
.	O
NF-kappa	O
B	O
activation	O
is	O
at	O
least	O
partially	O
dependent	O
on	O
oxidative	O
stress	O
,	O
since	O
the	O
antioxidant	O
thioctic	O
acid	O
significantly	O
lowered	O
the	O
extent	O
of	O
NF-kappa	B-protein
B	I-protein
binding	O
activity	O
.	O
Synergistic	O
activation	O
of	O
MAP	B-protein
kinase	I-protein
(	O
ERK1/2	O
)	O
by	O
erythropoietin	O
and	O
stem	B-protein
cell	I-protein
factor	I-protein
is	O
essential	O
for	O
expanded	O
erythropoiesis	O
.	O
Stem	B-protein
cell	I-protein
factor	I-protein
(	O
SCF	B-protein
)	O
and	O
erythropoietin	O
(	O
EPO	O
)	O
work	O
synergistically	O
to	O
support	O
erythropoiesis	O
,	O
but	O
the	O
mechanism	O
for	O
this	O
synergism	O
is	O
unknown	O
.	O
By	O
using	O
purified	O
human	O
erythroid	O
colony-forming	O
cells	O
(	O
ECFC	O
)	O
,	O
we	O
have	O
found	O
that	O
SCF	B-protein
and	O
EPO	O
synergistically	O
activate	O
MAP	B-protein
kinase	I-protein
(	O
MAPK	B-protein
,	O
ERK1/2	O
)	O
,	O
which	O
correlates	O
with	O
the	O
cell	O
growth	O
and	O
thus	O
may	O
be	O
responsible	O
for	O
the	O
synergistic	O
effects	O
.	O
Treatment	O
of	O
the	O
cells	O
with	O
PD98059	O
and	O
wortmannin	O
,	O
inhibitors	O
of	O
MEK	B-protein
and	O
PI-3	B-protein
kinase	I-protein
,	O
respectively	O
,	O
inhibited	O
the	O
synergistic	O
activation	O
of	O
MAPK	B-protein
and	O
also	O
the	O
cell	O
growth	O
,	O
further	O
supporting	O
this	O
conclusion	O
.	O
Wortmannin	O
only	O
inhibits	O
MAPK	B-protein
activation	O
induced	O
by	O
EPO	O
but	O
not	O
that	O
by	O
SCF	B-protein
,	O
suggesting	O
that	O
SCF	B-protein
and	O
EPO	B-protein
may	O
activate	O
MAPK	B-protein
through	O
different	O
pathways	O
,	O
which	O
would	O
facilitate	O
synergy	O
.	O
Furthermore	O
,	O
EPO	O
,	O
but	O
not	O
SCF	B-protein
,	O
led	O
to	O
activation	O
of	O
STAT5	B-protein
,	O
whereas	O
SCF	B-protein
and	O
wortmannin	O
had	O
no	O
effect	O
on	O
the	O
EPO	B-protein
-induced	O
STAT5	O
activation	O
,	O
suggesting	O
that	O
STAT5	B-protein
is	O
not	O
involved	O
in	O
the	O
synergistic	O
action	O
of	O
SCF	B-protein
and	O
EPO	O
.	O
Together	O
,	O
the	O
data	O
suggest	O
that	O
synergistic	O
activation	O
of	O
MAPK	B-protein
by	O
SCF	B-protein
and	O
EPO	B-protein
is	O
essential	O
for	O
expanded	O
erythropoiesis	O
.	O
Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O
The	O
molecular	O
and	O
phenotypic	O
profile	O
of	O
primary	O
central	O
nervous	O
system	O
lymphoma	O
identifies	O
distinct	O
categories	O
of	O
the	O
disease	O
and	O
is	O
consistent	O
with	O
histogenetic	O
derivation	O
from	O
germinal	O
center-related	O
B	O
cells	O
.	O
Primary	O
central	O
nervous	O
system	O
lymphoma	O
(	O
PCNSL	O
)	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
among	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
-infected	O
individuals	O
.	O
The	O
precise	O
histogenetic	O
derivation	O
and	O
the	O
molecular	O
pathogenesis	O
of	O
PCNSL	B-protein
is	O
poorly	O
understood	O
.	O
In	O
an	O
attempt	O
to	O
clarify	O
the	O
histogenesis	O
and	O
pathogenesis	O
of	O
these	O
lymphomas	O
,	O
49	O
PCNSL	O
(	O
26	O
acquired	O
immunodeficiency	O
syndrome	O
[	O
AIDS	O
]	O
-related	O
and	O
23	O
AIDS-unrelated	O
)	O
were	O
analyzed	O
for	O
multiple	O
biologic	O
markers	O
,	O
which	O
are	O
known	O
to	O
bear	O
histogenetic	O
and	O
pathogenetic	O
significance	O
for	O
mature	O
B-cell	O
neoplasms	O
.	O
PCNSL	B-protein
associated	O
frequently	O
(	O
50.0	O
%	O
)	O
with	O
mutations	O
of	O
BCL-6	B-protein
5	I-protein
'	O
noncoding	O
regions	O
,	O
which	O
are	O
regarded	O
as	O
a	O
marker	O
of	O
B-cell	O
transition	O
through	O
the	O
germinal	O
center	O
(	O
GC	O
)	O
.	O
Expression	O
of	O
BCL-6	B-protein
protein	I-protein
,	O
which	O
is	O
restricted	O
to	O
GC	O
B	O
cells	O
throughout	O
physiologic	O
B-cell	O
maturation	O
,	O
was	O
detected	O
in	O
100	O
%	O
AIDS-unrelated	O
PCNSL	O
and	O
in	O
56.2	O
%	O
AIDS-related	O
cases	O
.	O
Notably	O
,	O
among	O
AIDS-related	O
PCNSL	O
,	O
expression	O
of	O
BCL-6	O
was	O
mutually	O
exclusive	O
with	O
expression	O
of	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
-encoded	O
latent	O
membrane	O
protein	O
(	O
LMP	O
)	O
-1	O
and	O
,	O
with	O
few	O
exceptions	O
,	O
also	O
of	O
BCL-2	B-protein
.	O
All	O
but	O
one	O
PCNSL	O
expressed	O
hMSH2	O
,	O
which	O
among	O
mature	O
B	O
cells	O
selectively	O
stains	O
GC	O
B	O
cells	O
.	O
These	O
data	O
suggest	O
that	O
PCNSL	B-protein
may	O
be	O
frequently	O
related	O
to	O
GC	O
B	O
cells	O
and	O
may	O
be	O
segregated	O
into	O
two	O
major	O
biologic	O
categories	O
based	O
on	O
the	O
expression	O
pattern	O
of	O
BCL-6	O
,	O
LMP-1	O
,	O
and	O
BCL-2	B-protein
.	O
BCL-6	O
(	O
+	O
)	O
/	O
LMP-1	B-protein
(	O
-	O
)	O
/	O
BCL-2	B-protein
(	O
-	O
)	O
PCNSL	O
occur	O
both	O
in	O
the	O
presence	O
and	O
in	O
the	O
absence	O
of	O
HIV	O
infection	O
and	O
consistently	O
display	O
a	O
large	O
noncleaved	O
cell	O
morphology	O
.	O
Conversely	O
,	O
BCL-6	O
(	O
-	O
)	O
/	O
LMP-1	B-protein
(	O
+	O
)	O
/	O
BCL-2	B-protein
(	O
+	O
)	O
PCNSL	O
are	O
restricted	O
to	O
HIV-infected	O
hosts	O
and	O
are	O
represented	O
by	O
lymphomas	O
with	O
immunoblastic	O
features	O
.	O
These	O
data	O
are	O
relevant	O
for	O
the	O
pathogenesis	O
and	O
histogenesis	O
of	O
PCNSL	B-protein
and	O
may	O
be	O
helpful	O
to	O
segregate	O
distinct	O
biologic	O
and	O
prognostic	O
categories	O
of	O
these	O
lymphomas	O
.	O
Copyright	O
1998	O
by	O
The	O
American	O
Society	O
of	O
Hematology	O
.	O
Antioxidant	O
regulation	O
of	O
phorbol	O
ester-induced	O
adhesion	O
of	O
human	O
Jurkat	O
T-cells	O
to	O
endothelial	O
cells	O
.	O
Regulation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
and	O
function	O
by	O
reactive	O
oxygen	O
species	O
via	O
specific	O
redox	O
sensitive	O
mechanisms	O
have	O
been	O
reported	O
.	O
The	O
effects	O
of	O
clinically	O
safe	O
antioxidants	O
in	O
the	O
regulation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
in	O
human	O
endothelial	O
cells	O
(	O
ECV	O
)	O
,	O
and	O
adherence	O
of	O
human	O
Jurkat	O
T	O
cells	O
to	O
ECV	O
cells	O
were	O
investigated	O
.	O
The	O
thiol	O
antioxidant	O
,	O
alpha-lipoate	O
,	O
at	O
clinically	O
relevant	O
doses	O
down-regulated	O
phorbol	O
12-myristate	O
13-acetate	O
(	O
PMA	O
)	O
-induced	O
adhesion	B-protein
molecule	I-protein
expression	O
and	O
cell-cell	O
adhesion	O
.	O
Inhibition	O
of	O
PMA-induced	O
ICAM-1	O
and	O
VCAM-1	B-protein
expression	O
as	O
well	O
as	O
PMA-induced	O
adhesion	O
of	O
Jurkat	O
T-cells	O
to	O
ECV	O
cells	O
by	O
alpha-lipoate	O
was	O
dose	O
dependent	O
(	O
50-250	O
microM	O
)	O
.	O
The	O
effect	O
was	O
significant	O
for	O
ICAM-1	B-protein
(	O
p	O
<	O
.01	O
)	O
and	O
VCAM-1	B-protein
(	O
p	O
<	O
.01	O
)	O
expression	O
in	O
cells	O
pretreated	O
with	O
100	O
microM	O
alpha-lipoate	O
compared	O
to	O
PMA-activated	O
untreated	O
cells	O
.	O
Inhibition	O
of	O
PMA-induced	B-protein
adhesion	I-protein
molecule	I-protein
expression	O
and	O
cell-cell	O
adhesion	O
was	O
more	O
pronounced	O
when	O
a	O
combination	O
of	O
antioxidants	O
,	O
alpha-lipoate	O
and	O
alpha-tocopherol	O
,	O
were	O
used	O
compared	O
to	O
the	O
use	O
of	O
either	O
of	O
these	O
antioxidant	O
alone	O
.	O
The	O
regulation	O
of	O
adhesion	B-protein
molecule	I-protein
expression	O
and	O
function	O
by	O
low	O
concentration	O
of	O
antioxidants	O
investigated	O
does	O
not	O
appear	O
to	O
be	O
NF-kappaB	B-protein
regulated	O
or	O
transcription	O
dependent	O
because	O
no	O
change	O
in	O
the	O
mRNA	O
response	O
was	O
observed	O
.	O
Protein	B-protein
kinase	I-protein
C	I-protein
(	O
PKC	B-protein
)	O
has	O
been	O
suggested	O
to	O
regulate	O
PMA-induced	O
adhesion	O
molecule	O
expression	O
by	O
post-transcriptional	O
stabilization	O
of	O
adhesion	B-protein
molecule	I-protein
mRNA	O
.	O
Alpha-lipoate	O
pretreatment	O
did	O
not	O
influence	O
the	O
response	O
of	O
PKC	B-protein
activity	O
to	O
PMA	O
.	O
Oxidants	O
are	O
known	O
to	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
cell	O
adhesion	O
processes	O
.	O
Treatment	O
of	O
ECV	O
cells	O
with	O
PMA	O
induced	O
generation	O
of	O
intracellular	O
oxidants	O
.	O
Alpha-lipoate	O
(	O
100	O
or	O
250	O
microM	O
)	O
treatment	O
decreased	O
PMA-induced	O
generation	O
of	O
intracellular	O
oxidants	O
.	O
The	O
inhibitory	O
effect	O
of	O
low	O
concentration	O
of	O
alpha-lipaote	O
alone	O
or	O
in	O
combination	O
with	O
alpha-tocopherol	O
on	O
agonist-induced	O
adhesion	O
processes	O
observed	O
in	O
this	O
study	O
may	O
be	O
of	O
potential	O
therapeutic	O
value	O
.	O
Binding	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
to	O
CD4	B-protein
and	I-protein
CXCR4	I-protein
receptors	I-protein
differentially	O
regulates	O
expression	O
of	O
inflammatory	O
genes	O
and	O
activates	O
the	O
MEK	O
/ERK	O
signaling	O
pathway	O
.	O
We	O
have	O
previously	O
shown	O
that	O
binding	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
virions	O
to	O
CD4	B-protein
receptors	I-protein
stimulates	O
association	O
of	O
Lck	B-protein
with	O
Raf-1	O
and	O
results	O
in	O
the	O
activation	O
of	O
Raf-1	B-protein
kinase	I-protein
in	O
a	O
Ras-independent	O
manner	O
.	O
In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
HIV-1	O
envelope	O
glycoproteins	O
of	O
both	O
T-cell-tropic	O
and	O
macrophagetropic	O
strains	O
rapidly	O
activate	O
the	O
ERK/mitogen-activated	B-protein
protein	I-protein
(	O
MAP	O
)	O
kinase	O
pathway	O
and	O
the	O
binding	O
of	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
(	O
AP-1	B-protein
,	O
NF-kappaB	B-protein
,	O
and	O
C/EBP	O
)	O
and	O
stimulate	O
expression	O
of	O
cytokine	B-protein
and	O
chemokine	O
genes	O
.	O
The	O
activation	O
of	O
this	O
signaling	O
pathway	O
requires	O
functional	O
CD4	B-protein
receptors	I-protein
and	O
is	O
independent	O
of	O
binding	O
to	O
CXCR4	O
.	O
Binding	O
of	O
the	O
natural	B-protein
ligand	I-protein
stromal	I-protein
cell-derived	I-protein
factor	I-protein
1	I-protein
(	O
SDF-1	B-protein
)	O
to	O
CXCR4	O
,	O
which	O
inhibits	O
entry	O
of	O
T-cell-tropic	O
HIV-1	O
,	O
activates	O
also	O
the	O
ERK/	O
MAP	O
kinase	O
pathway	O
.	O
However	O
,	O
SDF-1	B-protein
did	O
not	O
affect	O
the	O
CD4-mediated	O
expression	O
of	O
cytokine	B-protein
and	O
chemokine	O
genes	O
.	O
These	O
results	O
provide	O
firm	O
molecular	O
evidence	O
that	O
binding	O
of	O
HIV-1	O
envelope	O
glycoproteins	O
to	O
CD4	B-protein
receptor	I-protein
initiates	O
a	O
signaling	O
pathway	O
(	O
s	O
)	O
independent	O
of	O
the	O
binding	O
to	O
the	O
chemokine	B-protein
receptor	I-protein
that	O
leads	O
to	O
the	O
aberrant	O
expression	O
of	O
inflammatory	O
genes	O
and	O
may	O
contribute	O
significantly	O
to	O
HIV-1	O
replication	O
as	O
well	O
as	O
to	O
deregulation	O
of	O
the	O
immune	O
system	O
.	O
Antigen	O
receptor	O
signaling	O
induces	O
MAP	O
kinase-mediated	O
phosphorylation	O
and	O
degradation	O
of	O
the	O
BCL-6	B-protein
transcription	I-protein
factor	I-protein
.	O
The	O
bcl-6	O
proto-oncogene	O
encodes	O
a	O
POZ/zinc	O
finger	O
transcriptional	O
repressor	O
expressed	O
in	O
germinal	O
center	O
(	O
GC	O
)	O
B	O
and	O
T	O
cells	O
and	O
required	O
for	O
GC	O
formation	O
and	O
antibody	B-protein
affinity	O
maturation	O
.	O
Deregulation	O
of	O
bcl-6	O
expression	O
by	O
chromosomal	O
rearrangements	O
and	O
point	O
mutations	O
of	O
the	O
bcl-6	O
promoter	O
region	O
are	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
B-cell	O
lymphoma	O
.	O
The	O
signals	O
regulating	O
bcl-6	O
expression	O
are	O
not	O
known	O
.	O
Here	O
we	O
show	O
that	O
antigen	O
receptor	O
activation	O
leads	O
to	O
BCL-6	O
phosphorylation	O
by	O
mitogen-activated	B-protein
protein	I-protein
kinase	I-protein
(	O
MAPK	B-protein
)	O
.	O
Phosphorylation	O
,	O
in	O
turn	O
,	O
targets	O
BCL-6	O
for	O
rapid	O
degradation	O
by	O
the	O
ubiquitin	O
/	O
proteasome	B-protein
pathway	O
.	O
These	O
findings	O
indicate	O
that	O
BCL-6	O
expression	O
is	O
directly	O
controlled	O
by	O
the	O
antigen	O
receptor	O
via	O
MAPK	B-protein
activation	O
.	O
This	O
signaling	O
pathway	O
may	O
be	O
crucial	O
for	O
the	O
control	O
of	O
B-cell	O
differentiation	O
and	O
antibody	O
response	O
and	O
has	O
implications	O
for	O
the	O
regulation	O
of	O
other	O
POZ/zinc	B-protein
finger	I-protein
transcription	I-protein
factors	I-protein
in	O
other	O
tissues	O
.	O
Glucocorticoid	B-protein
receptors	I-protein
are	O
differentially	O
expressed	O
in	O
the	O
cells	O
and	O
tissues	O
of	O
the	O
immune	O
system	O
.	O
Cytosolic	B-protein
glucocorticoid	I-protein
receptor	I-protein
(	O
GR	B-protein
)	O
binding	O
studies	O
on	O
immune	O
tissues	O
demonstrate	O
that	O
the	O
thymus	O
exhibits	O
three	O
to	O
four	O
times	O
higher	O
levels	O
of	O
GR	B-protein
protein	I-protein
than	O
the	O
spleen	O
.	O
High	O
levels	O
of	O
GR	B-protein
are	O
consistent	O
with	O
the	O
exquisite	O
sensitivity	O
of	O
the	O
thymus	O
to	O
glucocorticoid	O
exposure	O
.	O
Nevertheless	O
,	O
whole	O
cell	O
binding	O
studies	O
reveal	O
similar	O
levels	O
of	O
GR	B-protein
in	O
immature	O
thymic	O
T	O
lymphocytes	O
and	O
more	O
mature	O
,	O
splenic	O
T	O
lymphocytes	O
.	O
Moreover	O
,	O
whole	O
cell	O
binding	O
techniques	O
indicate	O
that	O
neutrophils	O
(	O
which	O
represent	O
roughly	O
30	O
%	O
of	O
splenic	O
leukocytes	O
)	O
exhibit	O
higher	O
GR	B-protein
than	O
both	O
T	O
and	O
B	O
lymphocytes	O
,	O
further	O
contradicting	O
results	O
from	O
cytosolic	O
binding	O
studies	O
.	O
To	O
address	O
these	O
inconsistencies	O
,	O
GR	B-protein
protein	I-protein
was	O
assessed	O
in	O
immune	O
cells	O
and	O
tissues	O
using	O
cytosolic	O
radioligand	O
binding	O
.	O
Western	O
blot	O
analysis	O
,	O
and	O
immunocytochemistry	O
.	O
Consistent	O
with	O
previous	B-protein
cytosolic	I-protein
receptor	I-protein
